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Selective Serotonin Reuptake Inhibitors (SSRIs) are the most frequently prescribed class of drugs 
worldwide and are implemented in the treatment of depression and other psychiatric disorders. 
SSRIs relieve depressive symptoms by modulating levels of the neurotransmitter serotonin in the 
brain. SSRIs block the function of the serotonin transporter, thereby increasing concentrations of 
extracellular serotonin. However, serotonin levels in the neurons of the brain only account for 5% 
while the remaining 95% is present outside the brain. Serotonin receptors and transporter are 
located on bone resident cells (mesenchymal stem cells (MSCs)), osteoblasts and osteoclasts, and 
serotonergic activity is believed to affect bone homeostasis. Consequently, alterations in serotonin 
levels by SSRI treatment have the potential to alter bone formation and remodeling. Clinical 
reports correlate increase risk of bone fractures and delayed bone healing with SSRI use. Metallic 
implants are commonly used as orthopedic and dental implants to fix bony defects. Surface 
modifications have been used to increase the level of bone to implant contact by controlling the 
differentiation of MSCs into an osteoblastic linage and facilitate bone production. However, it is 
not known if SSRIs can affect MSCs osteoblastic differentiation and bone remodeling signaling in 
response to microstructured biomaterials. The aims of this study were: 1) Investigate the effects of 
SSRIs on MSCs differentiation on microstructured titanium (Ti), 2) Determine the effects of SSRIs 
 
 
on bone remodeling signaling and osteoclast activation, and 3) Elucidate the effects of SSRIs on 
serotonin receptors and their effect on bone remodeling. To investigate this, human MSCs were 
grown on tissue culture polystyrene (TCPS), smooth Ti (PT) or microstructured Ti (SLA) surfaces 
under exposure to therapeutic concentrations of commonly prescribed antidepressants (SSRIs 
(fluoxetine, sertraline, paroxetine), Selective Norepinephrine Reuptake Inhibitor (SNRI) 
(duloxetine) and other regularly prescribed antidepressants (bupropion)) during differentiation 
toward osteoblasts. Osteoblastic differentiation was assessed in MSCs after treatment with the 
drugs (0.1μM, 1μM, 10μM) by alkaline phosphatase activity and osteocalcin levels. 
Antidepressant treatment decreased levels of MSC differentiation markers on microstructured Ti 
surfaces. Furthermore, treatment dose-dependently decreased protein levels secreted by MSCs 
which are important for bone formation (BMP2, VEGF, Osteoprotegerin), and increased those 
involved in bone resorption (RANKL). To determine the effect of SSRIs on bone remodeling 
signaling and osteoclast activation, human osteoclasts were either directly exposed to 
antidepressants or conditioned media obtained from MSCs treated with antidepressants on Ti 
surfaces, after which, enzymatic tartrate-resistant acid phosphatase (TRAP) activity was assessed. 
Antidepressants increased TRAP activity both directly and through treated MSCs, with the highest 
levels evident after treatment with conditioned media from MSCs on microstructured Ti surfaces. 
To elucidate the effects of serotonin receptors and their effect on bone remodeling, receptors were 
pharmacologically inhibited. Surface roughness decreased gene expression of HTR2A, HTR1B, 
and HTR2B, and antidepressant treatment increased their expression. Inhibition of HTR2A 
decreased RANKL protein levels, while inhibition of other serotonin receptors had no effect on 
RANKL or OPG levels. These studies suggest that antidepressants inhibit MSCs differentiation 
on microstructured Ti surfaces and increase levels of proteins associated with bone resorption. 
Additionally, our results showed that RANKL is regulated by serotonin receptor HTR2A. Taken 
together, our results suggest that antidepressants have a negative effect on osteoblastic 
differentiation, compromising bone formation and enhancing bone resorption, which can be 










1.1.  MAJOR DEPRESSIVE DISORDER 
Depression is a globally threatening psychiatric disorder, affecting approximately 350 
million people worldwide and rapidly becoming the leading cause of disability as rates continue 
to rise. [1]. Within the United States, the World Health Organization estimates that depression 
prevails in over 20% of the population, with a lifetime prevalence of about 15-20% [1]. In the 
adolescent population, the predominance of depression is reported to be as high as 8.3% [12]. 
Although no difference in rates are evident prior to puberty, among adolescence, however, rates 
are two to three times greater in females than males. This trend carries over into adulthood, as 
depression is twice as common in adult women when compared to men [12]. 
The illness is diagnosed by health care providers as “Major Depressive Disorder (MDD),” 
according to a set criteria of symptoms interrupting routine personal or occupational function, 
usually lasting longer than two weeks [1]. The disorder is thought to be caused by lower than 
normal neuronal serotonin production and synaptic availability [41]. MDD is chronic in nature, as 
an estimate of 80% of diagnosed individuals were reported to be prescribed an antidepressant for 
at least 12 months [28]. Currently, making the diagnosis of MDD is not based on a diagnostic 
examination, but rather a set of variable symptomatic criteria. Symptoms may be as mild as an 
unhappy mood, feelings of low self-esteem or decreased interest in activities once enjoyed, but 
can be as severe as diminished appetite and recurrent suicidal thoughts or actions. Regardless of 
the severity, its common practice to prescribe treatments for all cases of depression. 
1.2.  PHARMACOLOGICAL TREATMENTS OF MDD 
There are several treatment options for managing depressive symptoms. Psychological 
treatments are available through health care providers in the form of cognitive behavioral therapy 
and interpersonal psychotherapy [1]. However, pharmacological manipulation of the serotonergic 
system in the form of antidepressant medications has proven to be the most common and effective 
strategy for managing depression, and therefore, will be the focus of this work. Certain classes of 




pharmacological activity at specific action sites in the neurons of the brain. Despite this efficacy, 
however, they are known for their delayed onset of therapeutic action. Clinical symptoms of 
depression are generally not profoundly improved until 2-4 weeks of continuous pharmacological 
treatment, depending on the type of antidepressant [38]. Various types of antidepressants may 
differ in composition and efficacy, but all agents partake in some degree of modulation to the 
serotonergic system, however, at diverse selectivity. 
1.2.1. TRICYCLIC ANTIDEPRESSANTS (TCA) 
Many types of antidepressant medications are currently used for managing depression. 
Early generation antidepressants include Tricyclic Antidepressants (TCA) such as amitriptyline, 
clomipramine, imipramine and doxepin [12] and [27]. TCA treat depression by improving 
cholinergic, noradrenergic and/or serotonergic signaling in the brain [12]. Regardless of their 
success in resolving depressive symptoms, TCA act on adrenaline, choline and histamine 
receptors, which lead to presentation of undesirable side effects. Side effects such as drowsiness, 
dizziness, dry mouth and weight gain led to their infrequent prescription [12]. 
1.2.2. MONOAMINE OXIDASE INHIBITORS (MAOI) 
Monoamine oxidase inhibitors (MOAI) are a second type of early generation 
antidepressants. Many MOAI include phenelzine, tranylcypromine, isocarboxazid, selegiline and 
pargyline [12]. MOAI treat depression by inhibiting monoamine oxidases, which are catabolic 
enzymes responsible for serotonin degradation in the neurons of the brain. Inhibition of 
monoamine oxidase enzyme activity reduces serotonin degradation and prolongs its presence 
within presynaptic neurons of the brain for more efficient signaling with post synaptic neurons. 
Despite their efficacy, these drugs are also infrequently prescribed due to their non-specific 
interactions and associations with many adverse, and sometimes fatal, cardiac effects [12]. 
1.2.3. OTHER ANTIDEPRESSANTS 
Antidepressants are usually grouped by class due to their mechanism of action, however, 
some other types, such as trazodone and bupropion, do not belong to a specific category. These 
other medications are also frequently prescribed. Treatment of MDD using these other 
antidepressants is similar in mechanism as those described above, however, these types are less 




of neurotransmitters involved in modulation of mood in the brain, either separately or in addition 
to serotonin. These drugs are also very effective in treating depression. 
1.2.4. SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) 
Newer generation antidepressants, including Selective Norepinephrine Reuptake Inhibitors 
(SNRIs) have reliably shown to be effective in treating depressive symptoms and have much fewer 
side effects, partially due to their selectivity and specificity for the serotonin and norepinephrine 
neurotransmitters [12]. These medications treat depression by modulating levels of serotonin as 
well as norepinephrine in the brain. Medications in the SNRI class include duloxetine and 
venlafaxine [27].  
1.2.5. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
Selective Serotonin Reuptake Inhibitors (SSRIs) are currently the most widely prescribed 
family of medication in the treatment of depression, and thus, are the focus of this work. According 
to data obtained from the Prescription Pricing Authority, SSRI prescriptions drastically increased 
by 45% between the years 2000 and 2005, rapidly becoming the most prescribed class of 
antidepressants on the market [28]. This class of drugs include well-known medications like 
fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram, which are generic for Prozac, 
Zoloft, Paxil, Luvox and Celexa, respectively. Not only are SSRIs prescribed for treatment of 
MDD, but also for other psychological disorders, such as anxiety, and are consistently being 
prescribed for treatment of depression in expectant mothers [1]. 
1.2.5.1. SSRI MECHANISM OF ACTION 
SSRIs relieve depressive symptoms by modulating levels of the neurotransmitter serotonin 
in the neurons of the brain. A depressed mood corresponds with reduced serotonin 
neurotransmission within synaptic spaces [2]. Lower levels of serotonin weaken the signal 
transduction from one neuron to the next. One way to potentate this signal is to block the reuptake 
of extracellular serotonin molecules by the presynaptic neuron from the synapse. The serotonin 
transporter (5-HTT), also known as SERT, is a monoamine membrane transporter protein [2]. Its 
function is to transport extracellular serotonin from the synaptic spaces into presynaptic neurons. 
SSRIs have high affinity for 5-HTT. The binding of SSRIs to 5-HTT is very efficient in blocking 




prolongs, the duration of serotonergic activity (figure 1). This action will permit the presence of 
higher levels of serotonin and strengthen the signaling transduction from presynaptic to 
postsynaptic neurons, thereby treating depression. 
Although very effective in treating depression due to their high selectivity and potency for 
5-HTT, which enables them to increase serotonin levels in the brain, SSRIs increase systemic 
serotonin levels as well. High peripheral serotonin concentrations may have an impact on other 
cells within the body, such as bone cells. Mounting evidence links SSRI use with decreased bone 
mineral density, increased risk of fracture and dental implant failure [26] and [36]. Recent research 
suggests serotonin may be a substantial regulator involved in bone metabolism, and such effects 
are thought to be linked to serotonergic signaling. 
1.3.  SEROTONIN PRODUCTION AND FUNCTION 
Serotonin, also referred to as 5-hydroxytryptamine (5-HT), is a monoamine 
neurotransmitter and is well known as a mood regulator. It is responsible for mediating several of 
functions throughout the body, many of which include appetite, intestinal functions, sleep behavior 
and blood pressure regulation [22] and [27]. 5-HT is produced within the presynaptic neurons in 
the central nervous system as well as at other peripheral locations. Its production is carried out in 
a two-step biochemical process. The first step in synthesis involves hydroxylation of its precursor 
Figure 1: SSRI Mechanism of Action in the Neurons of the Brain. a) Normal physiological function. b) SSRI-




amino acid, L-tryptophan, into L-5-hydroxytryptophan. This is a rate-limiting reaction and is 
facilitated by an enzyme called tryptophan hydroxylase (TPH) [13]. There are two isoforms of the 
TPH enzyme, TPH1 and TPH2 [13]. Within the neurons of the brain, the TPH2 isoform is the one 
responsible for serotonin production. The second reaction in the production process involves a 
decarboxylation of the product obtained in the first reaction, which is achieved by an L-amino acid 
decarboxylase (DDC) enzyme (figure 1) [13]. Upon production, 5-HT is readily transported into 
secretory vesicles via vesicular monoamine transporters (VMAT) where it remains stored in 
presynaptic neurons [39]. 
In addition to synthesis within the raphe neurons of the brain stem, 5-HT is also synthesized 
throughout the gastrointestinal tract. Enterochromaffin cells (EC) lining the gut are the major 
source of peripheral 5-HT. EC are responsible for approximately 95% of circulating 5-HT levels 
in humans, and the remaining 5% is produced in the brain stem [6]. In the gut, 5-HT production 
takes place within the EC in a similar mechanism to central production, however, via TPH1. Once 
it is produced, 5-HT molecules may be released from the base of EC in response to external stimuli 
at the apical region of the cell [39]. When produced peripherally, the majority of serotonin in the 
gut is transported inside platelets within the blood for storage [11]. Platelets also possess 5-HTT 
on their membranes and are able to utilize it for 5-HT uptake. 
Depending on its site of synthesis, 5-HT has diverse functions. In the brain stem, 5-HT 
behaves as a neurotransmitter, where it is responsible for mood regulation [5]. Peripherally, 
however, it behaves as a hormone, signaling many cells as it travels through the blood stream [6]. 
Under normal physiological conditions, 5-HT cannot unreservedly cross the blood-brain barrier, 
and therefore, its function at one location should be thought of as independent of the other [5] and 
[6]. 
1.3.1. SEROTONIN AND BONE BIOLOGY 
Although poorly understood, increasing evidence proposes 5-HT to be a substantial factor 
in the regulation of bone quality and metabolism. 5-HT mediates its effects via membrane bound 
receptors within the 5-HTR1 and 5-HTR2 family, some of which are found on all major bone cell 
types, including, osteoblasts, osteoclasts and osteocytes [4] and [6]. Additionally, direct serotonin 




receptors and 5-HTT on bone cells, in addition to their ability to synthesize serotonin, suggests an 
important role for the neurotransmitter in bone metabolism, and therefore, complex cellular 
mechanisms may be affected by the excessive stimulation of these receptors with continual SSRI 
use. 
Increasing indications within the literature regarding the link between SSRI use and 
increased risks of fractures and markers of bone resorption are evident [26]. Studies investigating 
the effects of serotonergic signaling on bone quality utilized mice with a knockout gene for 5-
HTT. Their results revealed substantial decreases in bone density and architecture [37]. 
Furthermore, reports of SSRI bioaccumulation in the bone marrow are evident, and at much higher 
concentrations than those detected in the blood or neurons of the brain [36]. Serotonin produced 
within the central nervous system, however, seems to have the opposite effect, favoring bone mass 
accrual. The sympathetic nervous system is a known modulator of bone formation and resorption, 
favoring a decrease in bone mass accrual [27]. Serotonin produced centrally constrains such 
sympathetic output, enhancing bone mass accrual [27]. Furthermore, recent research involving 
mice with a Tph2-knockout, which is the enzyme responsible for 5-HT production in the brain, 
showed a reduction in number of osteoblasts, rate of bone formation and bone volume [27]. This 
suggests that serotonin may affect bone metabolism differently, depending on its origin. 
1.3.2. SEROTONERGIC SIGNALING IN BONE 
The majority of systemic 5-HT responsible for effects on bone is produced peripherally 
and kept inside platelets in the blood. Platelets also express 5-HTT, and are able to uptake 
extracellular 5-HT molecules from the blood and store it inside dense granules. Stored 5-HT 
molecules may be released upon activation or lysis of platelets. SSRI use may also raise 5-HT 
concentrations by blocking 5-HTT located on the platelets, inhibiting uptake of molecules from 
the surrounding space. This results in higher systemic 5-HT levels. 
Serotonin exerts its multitude of functions by signaling through its numerous receptors. 
The monoamine behaves as a hormone in the blood, as well as locally, in an autocrine and/or 
paracrine manor. It exhibits its effects through complex signaling mechanisms involving many of 
the serotonin receptors (5-HTR) located on plasma membranes of various cell types. Numerous 




focus of this work will be on those within the 5-HT1 and 5-HT2 families, as these are the ones 
known to be involved in modulating serotonergic effects on bone. 
Recent studies confirm the functionality of serotonin signaling in bone, with serotonin 
production by the EC of the gut being the most responsible for mediating skeletal effects. 
Peripheral serotonin found in the blood may bind to its HTR1B receptor located on osteoblasts and 
inhibit cAMP response element binding (CREB) protein. This protein is a transcription factor 
responsible for both positive and negative regulation of gene transcription. Serotonin signaling via 
HTR1B has been shown to inhibit Creb expression, and as a result, prevent osteoblastic 
proliferation [14]. 
1.3.2.1. 5-HT1 AND 5-HT2 RECEPTORS 
Serotonin receptors are composed of 7 different subfamilies, ranging from HTR1-7 [21], 
however, the focus of this work will be on those expressed in bone and involved in bone 
metabolism. The 5-HT1 receptor family includes 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D. Receptors 
within the 5-HT1 family are G-protein coupled receptors of the Gi class. They are coupled to two 
specific effector systems, where they are involved in inhibition of adenylyl cyclase activity, as 
well as opening of potassium (K+) channels [20]. Within the 5-HT1 family, this work will focus on 
the 5-HT1A and HTR1B receptors as they have been located on bone cells and their functions are 
involved in modulating bone metabolism. Many of the 5-HT1A receptors can be found within the 
hippocampus, hypothalamus, amygdala, as well as in the serotonergic cell body regions of the 
central nervous system [20]. 
Serotonergic neurons utilize various mechanisms for self-control and regulation, one of 
them involving the 5-HT1A receptor, an inhibitory, auto-receptor that is responsible for suppressing 
serotonergic activity. These receptors are activated by interactions with local serotonin. The 
binding of serotonin to 5-HT1A initiates the opening of K
+ channels, which leads to 
hyperpolarization of the cell membrane and ultimately, inhibition of cell firing [38]. Effects of 
antidepressants are more closely associated with the 5-HT1A receptor. It has been shown that long 
term treatment with antidepressants increases serotonergic transmissions via mechanisms 
mediated by the 5-HT1A receptor in the hippocampal regions of the brain [38]. Continuous 




enhances firing of 5-HT neurons for improved serotonergic transmission, promoting an anti-
depressive effect. 
The 5-HT2 receptors include 5-HT2A, 5-HT2B and 5-HT2C. They are located in the prefrontal 
cortex, hypothalamus, throughout the spinal cord, the choroid plexus, and the cerebral cortex [38] 
and [20]. All receptors within this family are responsible for stimulating phosphoinositide-specific 
phospholipase C (PI-PLC) [20]. These receptors are therefore thought to be involved in 
modulations of emotional states, cognitive functions and serotonergic activity [20]. Unlike the 
inhibitory effects of the 5-HT1A receptor, 5-HT2A activation results in an increase in pyramidal 
activity within the prefrontal cortex [38]. 
1.4. BIOMATERIALS 
Biomaterials are synthetic resources commonly used in clinical applications to aid in the 
healing and regeneration of damaged or diseased tissues. The main goal of a biomaterial is to 
integrate with the body and reinstate normal tissue functioning post disease or injury. Biomaterials 
applied in dental and orthopedic applications are utilized in the replacement of damaged hard 
tissues in events of atrophy, trauma or disease [18]. Dental implants are surgically anchored in 
bones of the jaw or skull in order to support tooth prosthetics. Successful biomaterials encourage 
healing post implantation by promoting new tissue formation while minimizing undesirable 
biological responses. 
Implant location and function determine a biomaterial’s requirements. In order for these 
materials to be successful in bone applications, they must exhibit excellent biocompatibility and 
provide great load-bearing capacity [17]. Dental applications require a biomaterial to possess high 
yield and fatigue strength to overcome cyclic loading forces present during mastication. Due to 
their suitable biomechanical properties, the most commonly used biomaterials for orthopedic and 
dental applications are metals. Pure titanium (Ti) as well as some of its alloys, predominately 
titanium, aluminum and vanadium (Ti6Al4V), are the most commonly used metals for dental 
applications [17]. 
1.5.  OSSEOINTEGRATION 
The success of biomaterials in dental implantology is largely dependent on interactions at 




formed bone must establish a firm and direct connection with the surface of the implanted material 
in order for it to be well secured and functional [7]. This process is referred to as osseointegration. 
An implant is acknowledged as successfully osseointegrated by the lack of relative movement at 
the connection between its surface and the bone. Implant characteristics, such as material type, 
surface topography and chemical composition can greatly influence this process. Other factors, 
such as the quality of the host bone or pharmacological agents are also great contributors to the 
success of this process. 
Implant failure due to inadequate osseointegration may be due to impaired healing 
responses, infections, such as peri-implantitis, or mechanical overloading [3]. Osseointegrated 
failures associated with the inability to properly heal are usually evident within the first few weeks 
or months post implantation [3]. Such early failures may be a result of the inability to of the implant 
to successfully osseointegrate with the surrounding bone as a result of poor bone formation or 
quality, causing mechanical instability and ultimate failure. Peri-implantitis related failures are 
usually evident in the second year after implantation [3]. 
1.6.  TITANIUM 
Some of the most widely used biomaterials for dental implant applications are composed 
of either pure or alloyed titanium (Ti) [17]. Commercially pure Ti has been used for many years 
in dental and orthopedic applications due to its corrosion resistance, high strength yet low modulus 
of elasticity and excellent biocompatibility [17] and [16]. Upon air exposure, Ti is able to 
spontaneously form a stable oxide layer on its surface [19]. This surface oxide film production is 
what allows the material to remain biologically inert and resistant to corrosion after implantation 
[19]. Increased biocompatibility elicits a favorable biological response to the implanted material, 
promoting bone formation and faster osseointegration. 
A dental implant’s success is highly dependent on the implanted material’s ability to 
encourage osseointegration. Once a dental implant is placed, it is initially minimally stabilized by 
frictional forces as it becomes interlocked between the existing bone within the jaw. For the 
implant to be successful, it must be firmly fixed by establishing direct contact with the surrounding 
bone tissue during the following weeks after implantation. The surrounding host bone tissue 




surrounding bone is remodeled, newly formed bone gets deposited on the implant’s surface, 
allowing for direct contact with the material. Although Ti has proven to be one of the best materials 
for such applications, dental implant failure remains a dilemma. Topographical modifications 
performed at the surface of the material are commonly used and can further enhance its clinical 
efficacy in dental applications. 
1.6.1. TOPOGRAPHICAL MODIFICATIONS 
A material’s surface topography has a crucial influence on cellular responses, and therefore 
is a great contributor to the general success or failure of a dental implant after it has been introduced 
in a host. In order to enhance the body’s biological response to an implant, topographical 
modifications can be applied at the implant surface. Altering material surface properties allows for 
control of cellular responses surrounding an implant, ultimately attaining efficacious clinical 
results. Since the majority of a dental implant’s success largely depends on cell-material 
interactions at its surface, topographical alterations can be done to enhance its success while still 
maintaining its desirable bulk material properties. Applying a superficial treatment to increase the 
material’s roughness and surface area allows for greater cell-implant adhesion. Increasing the 
surface roughness of an implant expands its surface area that is adjacent to bone tissue and 
encourages cellular attachment and proliferation. These events aid in improving the 
osseointegration process [29]. Modifications to a material’s surface can be made by utilizing 
additive or subtractive approaches [29]. Additive methods, such as a plasma sprayed 
hydroxyapatite or a calcium phosphate coating, involve applying a treatment to cover the 
material’s surface. Alternatively, subtractive methods involve either the removal of a portion of 
the material’s top surface or applying physical deformations to create a roughened 
microtopography. 
1.6.1.1. SANDBLASTING, LARGE-GRIT AND ACID ETCHING 
In order to improve a dental implant’s mechanical anchorage, numerous surface treatment 
techniques are performed to enhance the biological response of the material. Subtractive 
techniques, such as sandblasting and acid etching (SLA), are utilized to achieve roughened 
surfaces. Modifications to increases the surface energy (modified SLA/mSLA) are also used to 




grit sand elements followed by submersion in a heated, strong acid [29]. Such treatments not only 
clean the implant surfaces, but also create a micro-roughened superficial texture. mSLA surfaces 
are prepared from the same SLA technique, however, under nitrogen conditions to prevent 
hydrocarbon contamination and maintain hydrophilicity. 
Prior studies have shown that utilizing techniques to create rough surface topographies with 
high energy, such as SLA and mSLA surfaces, have proven to enhance cell attachment and 
osteoblastic lineage cell differentiation in comparison to smoother topographies [16] and [24]. By 
increasing the surface roughness, the material’s surface area also increases, thereby allowing a 
larger area for protein-cell-material interaction and improving cellular attachment and adhesion 
[29]. Furthermore, SLA surfaces mimic the normal physiological structure of remodeled bone. 
Thus, utilizing a topography that is most similar to that of the natural state provides for better 
contact between the implant’s surface and the surrounding bone and ultimately an improved 
healing response. 
1.7.  INITIAL INTERACTIONS BETWEEN CELLS AND MATERIALS 
Moments after an implant is introduced in the body, it makes contact with the host blood, 
where a sequence of cascading healing processes are initiated, beginning with protein adsorption. 
Figure 2: Quantitative scanning electron microscopy images and contact angle analyses of Ti surface 
topography. Images were taken at 5kx magnification for PT, SLA and mSLA surfaces with the corresponding 




Proteins present in the blood interact with and become adsorbed to the material’s surface until a 
monolayer is quickly formed. Inhabiting cells on a material’s surface do not actually attach to the 
surface directly, but rather to the layer of adsorbed proteins. Once the proteins are attached to the 
surface of the material, cells can make contact with these proteins and attach as well. This chemical 
bond formation at the cell-material interface is what promotes the healing process by facilitating 
implant fixation and reduced loosening. 
The composition and arrangement of proteins adsorbed at the implant surface is regulated 
by the material’s surface properties, such as chemical composition and microstructured topography 
[32]. Furthermore, this arrangement of the adsorbed proteins also influences the lineage 
progression of the attached cells by enhancing integrin binding [8]. Osteoprogenitor cells initiate 
attachment to the adsorbed layer of proteins on an implanted material via integrins. Integrins are 
transmembrane receptors, composed of α and β subunits, acting as bridges for cell-protein 
interactions [8] and [30]. The binding of integrins to the extracellular matrix (ECM) proteins 
induces mechanical stresses in the cytoskeleton of the cell, which stimulates intracellular signaling 
pathways involved in gene expression and osteogenic cell lineage differentiation [8].  
This process is critical for initiating osseointegration of the implant with the surrounding 
host bone. Studies supported this by showing that osteoblasts grown on roughened, 
microstructured Ti surfaces increased integrin gene expression when compared to smooth Ti and 
TCPS [30]. Thus, material surface properties do not only regulate protein adsorption on the 
implant’s surface, but also influences cellular attachment, adhesion and differentiation. 
1.8.  MESENCHYMAL STEM CELL DIFFERENTIATION 
The majority of the bones making up the mammalian skeleton, with the exception of the 
calvaria and other flat bones, originate from mesenchymal progenitors. Mesenchymal stem cells 
(MSCs) are known to be self-proliferative and multipotent. Given the proper stimuli, MSC are 
capable of differentiating into any of the following lineages: adipocyte, chondrocyte or osteogenic 
[15], [23] and [31]. MCSs reside in the bone marrow and the periosteum on the outside surface of 
bone, and in the presence of osteogenic supplements, are capable of differentiating into an 
osteoblastic lineage [31]. However, prior studies have demonstrated that rough, microstructured 




addition of osteogenic supplements [16]. Upon differentiation, osteoblasts form bone by creating 
and depositing bone matrix. 
MSCs are initially recruited from the bone marrow to the implant site through various 
signaling factors secreted by platelets and immune cells. The cells travel via blood and through the 
clot to reach the implant’s surface, where they bind to the adsorbed proteins on the implant surface 
via integrins and begin differentiating into an osteoblastic lineage. Differentiation of MSCs into 
an osteoblastic lineage involves complex cell-cell and cell-protein communication, which greatly 
contributes to an implant’s success. Multiple soluble factors produced and secreted by local and 
distal progenitors are required for the survival of these cells, as well as healing and regeneration 
surrounding the implant. Newly differentiated osteoblasts on the surface of the material allows the 
implant to become better integrated with the surrounding host bone. 
When MCSs are grown on microstructured Ti surfaces, without exogenous addition of 
osteogenic supplements, produce markers known to be expressed by osteoblasts during bone 
formation [8]. Initially, cells produce alkaline phosphatase (ALP) during early stages of 
differentiation and levels decline as the cells continue to later stages [34]. Expression of runt-
related transcription factor 2 (RUNX2) by osteoprogenitor cells is vital for bone formation. This 
protein belongs to the RUNX family and is a master transcription factor in regulating osteoblastic 
differentiation [25]. RUNX2 expression is upregulated in preosteoblast cells and is often measured 
as an early marker of osteoblastic differentiation [34]. ALP activity also reaches a peak prior to 
matrix mineralization and is a reliable measurement of early osteoblastic differentiation [40]. 
During later differentiation stages, Runx2 expression declines and osteoblasts produce and secrete 
osteoclacin (OCN), also known as bone gamma-carboxyglutamic acid-containing protein 
(BGLAP) [34] and [35]. This is a non-collagenous protein that is vital for bone mineralization, and 
it is promoted by the initial presence of Runx2 [34]. OCN is typically measured as a late marker 
of osteoblastic differentiation. 
1.9.  LOCAL FACTOR PRODUCTION 
MSC differentiation is heavily regulated in an autocrine and paracrine fashion by 
transcription and growth factors secreted from surrounding osteogenic cells at a distal location and 




MCSs in their journey to becoming osteoblasts, or bone forming cells. Osteogenic factor 
production is a key element in bone formation, osseointegration and implant success. Many of 
these molecules include osteogenic factors such as bone morphogenetic protein 2 (BMP2), which 
is a potent osteoinductive agent important for stimulating MSC differentiation towards an 
osteoblast [33].  
Bone formation requires access to blood supply, and for that reason, osteogenic cells 
produce and secrete factors like vascular endothelial growth factor (VEGF), an important agent 
for angiogenesis, or blood vessel formation [33]. Previous studies illustrated the capability of 
microstructured Ti surfaces in inducing greater levels of osteogenic factor production by MSC in 
comparison to smoother Ti topographies or tissue culture polystyrene (TCPS) surfaces [8]. 
Osteogenic lineage cells grown on such surfaces had greater production of osteogenic factors such 
as BMP-2 and angiogenic growth factor production of VEGF was also enhanced [8] and [30]. The 
microenvironment maintained by distal osteogenic cells is also important for proper bone 
formation. Local factor production of other important proteins by osteogenic cells regulate the 
bone remodeling process. This process is vital for preserving bone density and quality. Even slight 
misregulation in this process can have substantial effects on the normal bone physiology. 
1.10. BONE REMODELING 
The skeletal system is a highly dynamic organ that is responsive to various stimuli, and as 
a result, is continuously renewed. Bone tissue is in a constant state of renovation, as controlled by 
two types of specialized cells: osteoblasts and osteoclasts. This process, known as bone 
remodeling, involves the removal of superficial cortical and trabecular bone by osteoclasts, 
followed by its subsequent replacement with new bone matrix deposited by osteoblasts [25]. MCSs 
are the precursors for osteoblasts, while osteoclasts are giant, multinucleated cells originating from 
hematopoietic cells of the monocyte and macrophage lineage [21] and [13]. In the presence of 
macrophage-colony stimulating factor (M-CSF) and receptor activator for NF-KB ligand 
(RANKL), osteoclast precursors are known to differentiate into mature osteoclasts [45]. M-CSF 
promotes development and expression of receptor activator of NF-KB (RANK), a receptor for 




Bone remodeling is sensitive to various stimuli and can be altered by the mechanical forces 
of walking or systemic hormonal fluctuations [22]. Continuously renewing mineralized tissue 
ensures proper growth, maintenance and repair of the skeletal system. Under normal physiological 
conditions, tissue formation precedes at a similar rate as matrix resorption, and in a site-specific 
manner, in order to maintain adequate bone quality. Thus, osteoblasts and osteoclasts must 
simultaneously coordinate their activities to balance formation with resorption. Mineralized bone 
is resorbed by the osteoclasts, creating resorption pits. These resorbed areas become replaced with 
newly formed bone matrix by the osteoblasts [30]. In order for this process to be tightly controlled, 
the specialized cells produce and secrete local factors for communication with one another. 
1.10.1. OPG, RANK AND RANKL 
Bone remodeling is largely regulated by RANK, RANKL and its decoy receptor, 
osteoprotegerin (OPG) [25] and [22]. Local regulation of these secreted factors is vital for 
modulating bone remodeling and balancing the rate of bone formation with resorption. 
Osteoblastic lineage cells produce RANKL throughout their differentiation process. RANKL is an 
essential protein involved in the formation, activation and function of osteoclastic cells [25]. 
Stimulation of RANK by RANKL on osteoclasts promotes osteoclastogenesis and osteoclastic 
activity. The binding of RANKL to its receptor, RANK, on the surface of osteoclast precursors 
promotes the fusion and formation of a multinucleated osteoclast. RANKL/RANK interactions 
also activate and initiate bone resorption on mature osteoclasts [25]. Bone resorption is marked by 
higher levels of osteoclastic activity, which relates to increased production of tartrate-resistant acid 
phosphatase (TRAP).  Osteoclasts differentiated from the monocyte lineage are known to produce 
and secrete TRAP enzymes on the surface of the bone matrix. Mature osteoclasts participate in 
bone remolding by increasing this enzymatic activity at their ruffled borders on the surface of 
bone, creating various resorption pits. In order to regulate osteoclastic activity, osteoblastic lineage 
cells also produce and secrete OPG as a means for overriding bone resorption. OPG binds to 
RANKL in order to prevent its binding to RANK on the osteoclast surface, thereby reducing 
osteoclastic activation and resorption [25]. Therefore, bone remodeling is controlled by the relative 




osteoblasts and osteoclasts. Imbalances in secreted RANKL/OPG ratios by osteogenic cells 
disrupts baseline levels and has the potential to affect the quality of bone. 
1.11. SSRI USE AND DENTAL IMPLANTS 
SSRIs are the most effective in treating depression due to their high selectivity and potency 
for 5-HTT, which enables them to increase serotonin levels in the brain in much higher 
concentrations when compared to other types of antidepressants. However, SSRIs increase 
systemic serotonin levels as well, and elevated peripheral serotonin concentrations may have a 
detrimental impact on other cells in the body, such as bone cells. Recent research suggests 
serotonin as a substantial regulator involved in physiological control of bone mass, and such effects 
are thought to be linked to serotonergic signaling in bone. Taking into account SSRI influence on 
peripheral serotonin concentrations, chronic use may severely affect bone remodeling and quality, 
ultimately reducing implanted biomaterials’ success. 
Although dental implants are very successful in establishing a firm connection with the 
host bone, implant failures remain evident in patients compromised by disease, old age or chronic 
prescription use. Implant success is not only dependent on secured stabilization, but also on the 
quality of the recipient’s bone which surrounds the implanted material. Mounting evidence links 
SSRI use with decreased bone mineral density, increased risk of fracture and dental implant failure 
as compared to nonusers [3, 26 and 36]. Failures were shown to occur between the first 4 and 18 
months post implantation [3]. Excessive peripheral serotonergic signaling may disrupt 
maintenance of skeletal remodeling processes required for preservation of healthy bone quality 
and adaptation to mechanical stimuli, and therefore, may be the probable cause of dental implant 
failure. 
The use of dental implants is becoming increasingly popular in the United States, as more 
than 5 million are placed per year, and numbers are expected to continue increasing by an annual 
rate of 15% [43]. These statistics are alarming when taken in consideration with the overwhelming 
depression rates and SSRI use. Bioaccumulation of SSRIs in the bone marrow is also a major 
concern, as the drugs are known to sequester in those locations at much greater concentrations than 
those in the blood or brain. Due to the chronic nature of MDD, it is standard practice for newly 




[28]. However, most patients continue this regimen for much longer periods, and in some cases, 
throughout their lifetime. Thus, SSRI use may have deleterious effects on the healing and 
regeneration capability of progenitor cells recruited from reservoirs in the bone marrow for new 
bone formation surrounding an implanted biomaterial. 
1.12. SPECIFIC AIMS 
In order to be successful, an implanted material must osseointegrate with the surrounding 
host bone to establish a firm connection. Since this process is highly dependent on the quality of 
host bone, recipients taking medications affecting bone metabolic mechanisms, such as 
antidepressants, increase their risk of osseointegrated implant failure. The main objective of this 
research is to understand how antidepressants can affect bone formation by MSC differentiation 
and local protein production in the microenvironment by these cells on clinically relevant Ti 
biomaterials commonly used in dental applications. Studies in this work utilize a novel in vitro 
model for human osteoblastic differentiation from early MSC precursors using only Ti surface 
characteristics to induce differentiation into mature osteoblasts. This model was used as a tool to 
investigate the effects of antidepressants on dental implant failure by assessing their effect on bone 
formation by osteoblastic differentiation and bone resorption by osteoclastic TRAP activity, and 
how these effects can be modulated by the implant’s surface characteristics. The main hypothesis 
is that antidepressants will prevent human MSC differentiation, decrease local protein production 
associated with bone formation and quality and increase proteins involved in bone resorption 
surrounding Ti biomaterials, ultimately delaying the osseointegration process and diminishing 
dental implant success. 
Specific Aim 1: Investigate the effects of SSRIs on MSC differentiation on 
microstructured Ti. Antidepressants exhibit their therapeutic effects by modulating extracellular 
levels of serotonin. It has been shown that serotonin is involved in bone metabolism and all major 
types of bone cells possess serotonin receptors and the transporter. Microstructured Ti surfaces 
enhance MSC differentiation by increasing local angiogenic and osteogenic factor expression and 
production. However, effects of antidepressants on MSC differentiation during interactions with 
Ti surfaces have yet to be determined. The objective of this aim will be to assess the effects of 




differentiation markers and local factor production by cells cultured on smooth (PT) or 
microstructured (SLA) Ti and compared to TCPS surfaces. The hypothesis for this aim is that 
human MSC differentiation will be enhanced by Ti surface roughness, however, treatment with 
antidepressants will prevent differentiation, with SSRIs having the most detrimental effects on 
osteoblastic differentiation in comparison to other classes of antidepressants. Levels of proteins 
associated with bone formation, modulators of bone remodeling, angiogenesis and markers of 
osteoblastic differentiation will be measured. Since antidepressants modulate levels of serotonin, 
the effects of serotonin treatment on MSC differentiation and local factor production will also be 
investigated.  
Specific Aim 2: Determine the effects of SSRIs on bone remodeling signaling and 
osteoclast activation. Osteoclastic activity is initiated by the binding of RANKL to its receptor, 
RANK, on the osteoclast surface. Higher osteoblastic secretions of RANKL increase production 
of TRAP by osteoclasts and promote bone resorption. Misregulation of the RANKL/OPG ratio in 
the microenvironment has negative consequences on the quality of bone and ultimately 
osseointegration of implants. The objective of this aim is to understand how direct exposure of 
osteoclast precursors to antidepressants, or exposure to factors in the microenvironment in 
conditioned media obtained from MSCs treated with antidepressants, can affect osteoclastic 
activity. The hypothesis is that treatment of osteoclasts with antidepressants, or conditioned media 
from MSCs treated with antidepressants, will increase osteoclastic TRAP activity. For this aim, 
MCS-F and RANKL-treated osteoclast precursors will be directly exposed to antidepressants or 
conditioned media and TRAP enzymatic activity will be assessed.  
Specific Aim 3: Elucidate the effects of SSRIs on serotonin receptors and their effect 
on bone remodeling. Bone cells utilize serotonin in metabolic processes and express serotonin 
receptors and serotonin transporters on their cell membranes. However, whether surface 
characteristics of Ti biomaterials can modulate MSC gene expression of serotonin receptors has 
not been determined. The objective of this aim will be to confirm if surface roughness and 
wettability can alter expression of serotonin receptors by human MSCs, and how this expression 
can be modulated with antidepressant treatment. Additionally, the role of MSC serotonin receptors 




characteristics will alter MSC gene expression of serotonin receptors, as well as OPG and RANKL 
protein production, and treatment with antidepressants will modulate these effects. For this aim, 
mRNA levels of MSC serotonin receptors on smooth or rough Ti surfaces with and without 
serotonin or antidepressant treatments will be examined and compared to TCPS surfaces. To 
determine whether serotonin receptors are involved in OPG and RANKL production, MSCs will 
be grown on smooth or rough Ti surfaces and treated with specific inhibitors for each serotonin 
receptor in the presence of physiological concentrations of serotonin. Protein levels for OPG and 





CHAPTER 2 METHODS, MATERIALS AND RESEARCH DESIGN 
 
 
2.1. SPECIFIC AIM 1: INVESTIGATE THE EFFECTS OF SSRIS ON HUMAN MSC 
DIFFERENTIATION ON MICROSTRUCTURED TI 
Studies performed in aim 1 are to determine the differentiation capability of human MSCs 
on various Ti surfaces under exposure to most frequently prescribed antidepressants within the 
SSRI class (fluoxetine, sertraline and paroxetine), the SNRI class (duloxetine) as well as other 
antidepressants not belonging to a specific category (trazodone and bupropion). Since 
antidepressants increase extracellular serotonin concentrations in the body, the effects of serotonin 
treatments on MSC differentiation was also assessed as a positive control. Cells not treated with 
serotonin or antidepressants were a negative control. The hypothesis is that treatment with 
antidepressants will prevent MSC differentiation. 
2.1.1. AIM 1.1: DETERMINE THE EFFECTS OF ANTIDEPRESSANT TREATMENT 
ON MSC DIFFERENTIATION WHILE CULTURED ON SMOOTH VS. ROUGH 
TI SURFACES 
The purpose of aim 1.1 is to examine whether antidepressant treatment prevents 
osteoblastic differentiation of MSCs, and how this is affected by increases in surface roughness. 
For these studies, clinically relevant Ti surfaces utilized in dental implant applications were used 
to assess differentiation capability. All surfaces used in these studies were generated by producing 
15mm diameter cut outs from grade 2 unalloyed Ti sheets of 1mm thickness obtained from Institut 
Straumann AG (Basel, Switzerland). Disks were cut out into 15mm to ensure an accurate fit in the 
wells of a 24 well tissue culture plate. Smooth, pretreatment (PT) surfaces were created by treating 
the disks with acetone for degreasing purposes, then processing in a 55°C 2% ammonium 
fluoride/2% hydrofluoric acid/10% nitric acid solution for 30 seconds. Rough (SLA) surfaces were 
created by sand blasting and acid etching PT surfaces with 0.25-0.50mm corundum grit and 
HCl/H2SO4, respectively. 
Human bone marrow-derived MCSs (Lonza, Walkersville, MD) were commercially 
obtained. Cells with passages between 4 and 5 were plated at a 10,000 cells/cm2 density in the 




Medium (MSCGM, Lonza). PT and SLA disks were placed in the wells of a 24 well plate  
(n=6) and MSCs were cultured on the surface of the disks (figure 3). Cells were cultured on TCPS, 
PT or SLA surfaces at 37°C with 5% CO2 and 100% humidity. MSCs were grown for 7 days in 
MSCGM and in the absence of exogenous supplements. In prior studies, MSCs have been shown 
to produce an osteoblastic phenotype after 7 days of culture on microstructured Ti surfaces, 
without the addition of osteoblastic differentiation supplements [31]. The same model of 
differentiation was adapted for MSC differentiation studies in this aim and in all upcoming studies 
in this work. 
For pharmacological treatments, cells were treated with either an antidepressant or 
serotonin. Agents including bupropion, duloxetine, fluoxetine, serotonin, sertraline, paroxetine 
and trazodone (Cayman Chemical) were reconstituted in DMSO (Sigma) to stock concentrations 
of 1mM or 10mM and stored at -20°C. Human MSC were cultured as described above and media 
was changed after the first 24 hours post plating, then again every 48 hours for the remainder of 
the 7 days. Cells were treated with either 1μM or 10μM concentrations of media containing either 
an SSRI (fluoxetine, sertraline and paroxetine), an SNRI (duloxetine), another antidepressant 
Figure 3: Specific Aim 1 Research Design. Human MSCs were cultured on TCPS, PT or SLA surfaces in 
MSCGM for 7 days throughout differentiation while being exposed to 0.1μM, 1μM or 10μM concentrations of 
antidepressants within the SSRI or SNRI categories, as well as other types of commonly prescribed 
antidepressants. Gene expression and protein levels for early and late osteoblastic differentiation markers and 




(trazodone and bupropion) or serotonin for 7 days throughout their differentiation. 
Pharmacologically treated cells were compared to cells cultured with media containing 10μM of 
DMSO as the control. After 7 days, all cells were incubated with fresh MSCGM for 24 hours, 
without any pharmacological treatment. After 24 hours, conditioned media was collected, cells 
were harvested from each surface and lysed. ALP activity (early osteoblastic differentiation 
marker) was assessed and normalized to total protein content in each well. An Enzyme-Linked 
Immunosorbent Assay (ELISA) was used to measure protein levels for OCN (late osteoblastic 
differentiation marker) (AlfaAesar). OCN protein levels were normalized to total DNA content in 
each well using a Quant-iTTM PicoGreen dsDNA Assay Kit (Life Technologies) in cell lysates, 
measured according to the manufacturer’s instructions. 
In a second study investigating effects of antidepressants on osteoblastic gene expression, 
MSCs were cultured for 7 days and treated with either an antidepressant or serotonin, as described 
above. After 7 days, all cells were incubated with fresh MSCGM for 12 hours, without any 
pharmacological treatment. Cell supernatants were collected after 12 hours, cells were harvested 
and RNA was extracted using the TRIzol® (Life Technologies) extraction technique. NanoDrop 
spectrophotometer (Thermo Scientific, Waltham, Massachusetts) was utilized to quantify mRNA. 
To convert RNA to complementary DNA (cDNA), reverse transcription polymerase chain reaction 
(RT-PCR) was performed on 750ng of RNA using a High Capacity Reverse Transcription cDNA 
Kit (Life Technologies). Real-time quantitative polymerase chain reaction (qPCR) was performed 
for analysis of RUNX2 (early) and OCN (late) osteoblastic differentiation genes using Power 
SYBR® Green Master Mix (Life Technologies) and primers specific to each gene of interest in 
StepOnePlus Real-Time PCR Systems (Life Technologies). A standard curve was generated using 
human MSCs cultured on TCPS and all gene expression was normalized to the expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
2.1.2. AIM 1.2: DETERMINE THE EFFECTS OF ANTIDEPRESSANT TREATMENT 
ON MSC LOCAL FACTOR PRODCUTION OF BMP2, OPG, RANKL AND 
VEGF PROTEIN LEVELS IN THE MICROENVIRONMENT ON TI SURFACES 
The purpose of aim 1.2 is to determine if antidepressant treatments affect MSC protein 
production in the microenvironment and if these effects can be modulated by increases in surface 




concentrations of media containing either an SSRI (fluoxetine, sertraline and paroxetine), an SNRI 
(duloxetine), other types of antidepressants (trazodone and bupropion) or serotonin were given to 
cells for 7 days throughout differentiation. Pharmacologically treated cells were compared to cells 
cultured with media containing 10μM of DMSO as the control. After 7 days, all cells were 
incubated with fresh MSCGM for 24 hours, without any pharmacological treatment. After 
incubation in fresh MSCGM for 24 hours, conditioned media was collected. ELISA (PeproTech) 
was used to measure secreted protein levels in the media for BMP-2 (osteogenic marker), RANKL 
(osteoclast activator) and VEGF (angiogenic factor) according to the manufacture’s protocol. 
Secreted protein levels for OPG (osteoclast inhibitor) (DuoSet ELISA) were also measured. All 
secreted protein levels were normalized to total DNA content within each well using a Quant-
iTTM PicoGreen dsDNA Assay Kit (Life Technologies) in cell lysates, according to the 
manufacturer’s instructions. 
2.2. SPECIFIC AIM 2: DETERMINE THE EFFECTS OF SSRIS ON BONE 
REMODELING SIGNALING AND OSTEOCLAST ACTIVATION 
Studies performed in aim 2 are designed to assess whether effects of antidepressants on 
MSC production of the microenvironment can affect osteoclastic TRAP activity. In these studies, 
osteoclast precursors will be either directly exposed to antidepressants or conditioned media 
obtained from MSCs treated with antidepressants. The hypothesis is that treatment of osteoclasts 
with antidepressants, or conditioned media from MSCs treated with antidepressants, will increase 
osteoclastic TRAP activity. 
2.2.1. AIM 2.1: DETERMINE THE DIRECT EFFECTS OF ANTIDEPRESSANTS ON 
OSTEOCLASTIC ACTIVITY 
Studies in aim 2.1 will be performed to explore whether directly treating osteoclasts with 
antidepressants affects their osteoclastic TRAP activity. Primary human CD14+ monocytes 
isolated from peripheral blood were obtained commercially (StemCell Technologies). 
Approximately 50,000 cells were plated per well in a collagen-coated 48 well plate and cultured 
in .250mL per well of Roswell Park Memorial Institute (RPMI) medium 1640 (Fisher Scientific) 




differentiated to osteoclasts through RPMI media treated with 20ng/mL and 50ng/mL of human 
M-CSF and RANKL (Peprotech) supplements for 7 days and media was changed every 3 days. 
Cells were treated with 1μM or 10μM concentrations of RPMI media containing an SSRI 
(fluoxetine or sertraline), an SNRI (duloxetine), or serotonin for 7 days (figure 4). 
Pharmacologically treated cells were compared to cells cultured with media containing 10μM of 
DMSO as the control. Osteoclastic TRAP activity was assessed by measuring total acid 
phosphatase activity in cell lysates, which was quantified using an Acid Phosphatase Colorimetric 
Assay Kit (Cayman Chemical), according to the manufacturer’s instructions. Colorimetric changes 
were measured at a wavelength of 405nm and TRAP activity was normalized to protein levels per 
well. 
2.2.2. AIM 2.2: DETERMINE THE EFFECTS OF CONDITIONED MEDIA FROM 
MSCS TREATED WITH ANTIDEPRESSANTS ON OSTEOCLASTIC 
ACTIVITY 
Studies in aim 2.2 will determine if exposing osteoclasts to the microenvironment 
generated by MSCs after their treatment with antidepressants has the potential to affect osteoclastic 
TRAP activity. For these studies, human MSCs and monocytes were cultured simultaneously and 
as previously described (figure 5). MSCs were plated on PT, SLA or TCPS surfaces and treated 
with MSCGM containing either an SSRI (fluoxetine and sertraline), an SNRI (duloxetine), or 
serotonin in 1μM or 10μM concentrations for 7 days throughout differentiation. Media was 
changed in the first 24 hours post plating, then again every 48 hours for the remainder of the 7 
Figure 4: Aim 2.1 Research Design. Primary human CD14+ monocytes were cultured on collagen I coated 
surfaces in RPMI supplemented with 20ng/mL human M-CSF and 50ng/mL RANKL for 7 days while being 
exposed to 1μM or 10μM concentrations of antidepressants within the SSRI or SNRI categories. Osteoclastic 




days. After 7 days, MSCs were incubated with fresh Dulbecco’s Modification of Eagle’s Medium 
(DMEM) (VWR) for 24 hours, without any pharmacological treatment. Conditioned media was 
collected on day 7 and used to treat osteoclasts. 
Monocytes were simultaneously plated on collagen-coated surfaces as previously 
described and treated with RPMI media supplemented with 20ng/mL and 50ng/mL of human M-
CSF and RANKL during the same 7 days as the MSCs. On day 7, RPMI media was discarded, and 
cells were treated with .250mL per well of the conditioned media collected from the MSCs for 48 
hours, then cells were harvested and osteoclastic TRAP activity was assessed in cell lysates using 
Acid Phosphatase Colorimetric Assay Kit as previously described in the prior study and TRAP 
activity was normalized to protein levels per well. 
2.3. SPECIFIC AIM 3: ELUCIDATE THE EFFECTS OF SSRIS ON SEROTONIN 
RECEPTORS AND THEIR EFFECTS ON BONE REMODELING 
The main purpose of aim 3 is to confirm if surface characteristics can alter expression of 
serotonin receptors by human MSCs, and how this expression can be modulated with 
antidepressant treatments. In addition, the role of serotonin receptors in the production of OPG 
and RANKL by MSCs will also be assessed to investigate if receptor behavior affects processes 
involved in bone remodeling. The hypothesis for this aim is that surface characteristics will alter 
Figure 5: Aim 2.2 Research Design. MCS-F and RANKL-stimulated CD14+ monocytes were exposed to 
conditioned media collected from MSCs treated with concentrations of 0μM, 1μM or 10μM of fluoxetine, 




MSC gene expression of serotonin receptors, as well as OPG and RANKL protein production, and 
treatment with antidepressants will further modulate these effects. 
2.3.1. AIM 3.1: DETERMINE THE EFFECTS OF TI SURFACE CHARACTERISTICS 
ON HUMAN MSC SEROTONIN RECEPTOR GENE EXPRESSION 
Studies in aim 3.1 will be performed to study the effects of surface roughness and 
wettability on serotonin receptor gene expression. For this studies in this aim, human MSCs were 
cultured on PT (smooth), SLA (rough and hydrophobic), or mSLA (rough and hydrophilic) Ti 
surfaces and compared to those on TCPS. Cells were cultured in MSCGM for 7 days as previously 
described. Cell supernatants were collected after 12 hours of incubation, cells were harvested and 
RNA was extracted using the extraction technique described above. Levels of human MSC mRNA 
were quantified and cDNA was obtained by preforming RT-PCR. For gene expression analysis, 
qPCR was performed for the following serotonin receptor genes: HTR1A, HTR2A, HTR1B and 
HTR2B. A standard curve was generated using human MSCs cultured on TCPS and all gene 
expression was normalized to the expression of GAPDH (figure 6). 
2.3.2. AIM 3.2: EXAMINE THE EFFECTS OF ANTIDEPRESSANTS AND TI 
SURFACE CHARACTERISTICS ON HUMAN MSC SEROTONIN RECEPTOR 
GENE EXPRESSION 
Experiments performed in aim 3.2 were to determine if antidepressants affect serotonin 
receptor expression by human MSCs, and how this expression is affected by surface roughness 
Figure 6: Aim 3.1 Research Design. Human MSCs were cultured on TCPS, PT, SLA or mSLA surfaces in 
MSCGM for 7 days throughout differentiation. Gene expression of HTR1A, HTR1B, HTR2A and HTR2B 




when the cells are cultured on rough vs. smooth Ti surfaces. Human MSCs were cultured and 
grown as previously described. Briefly, cells were exposed to 0.1μM, 1μM or 10μM concentrations 
of MSCGM containing antidepressants within the SSRI family (fluoxetine, sertraline or 
paroxetine), SNRI family (duloxetine), other antidepressants (trazodone or bupropion) or serotonin 
while plated on PT or SLA surface and compared with those on TCPS (figure 7). Serotonin 
treatments were used as the positive control while treatments with 10μM concentrations of DMSO 
in media were used as the no treatment control. Cell supernatants were collected after 12 hours of 
incubation, cells were harvested and RNA was extracted using the extraction technique described 
above. Levels of human MSC mRNA were quantified and cDNA was obtained by preforming RT-
PCR. For gene expression analysis, qPCR was performed for the following serotonin receptor 
genes: HTR1A, HTR2A, HTR1B and HTR2B. A standard curve was generated using human 
MSCs cultured on TCPS and all gene expression was normalized to the expression of GAPDH. 
2.3.3. AIM 3.3: DETERMINE THE EFFECTS OF SEROTONIN RECEPTOR 
INHIBITION ON HUMAN MSC PRODUCTION OF OPG AND RANKL ON TI 
SURFACES 
The purpose of aim 3.3 is to determine the effect of serotonin receptors in modulating bone 
remodeling processes by human MSC production of OPG and RANKL. For this aim, serotonin 
Figure 7: Aim 3.2 Research Design. Human MSCs were cultured on TCPS, PT or SLA surfaces in MSCGM for 
7 days throughout differentiation while being exposed to 1μM or 10μM concentrations of serotonin or 
antidepressants within the SSRI or SNRI categories, as well as other antidepressants. Gene expression of HTR1A, 




receptors on human MSCs will be pharmacologically blocked using specific inhibitors while the 
cells are plated on smooth vs. rough Ti surfaces and OPG and RANKL protein levels will be 
measured. Human MSCs were cultured as previously described on PT or SLA surfaces and 
compared to those on TCPS and grown in the presence of MSCGM containing 1μM concentrations 
of the following serotonin receptor inhibitors: WAY-100635 (HTR1A), RH-34 (HTR2A), SB-
224289 (HTR1B), RS-127445 (HTR2B) (Cayman Chemical), or a combination of all 4. 
Pharmacologically treated cells were compared to cells cultured with media containing 1μM of 
DMSO as the control. After 7 days, all cells were incubated with fresh MSCGM for 24 hours, 
without any pharmacological treatment. All cells were incubated with fresh MSCGM on day 7 for 
24 hours, without any pharmacological treatment. After 24 hours, conditioned media was 
collected, cells were harvested from each surface and lysed. OPG and RANKL secreted protein 
levels in the media were assessed with ELISA and normalized to total DNA content of cell lysates 





CHAPTER 3 RESULTS 
  
3.1. SPECIFIC AIM 1: INVESTIGATE THE EFFECTS OF ANTIDEPRESSANTS ON 
HUMAN MSC DIFFERENTIATION ON TI SURFACES 
 
DNA Quantification on Surfaces 
The response of human MSCs to Ti substrates and the TCPS control during exposure to 
serotonin or antidepressants was assessed by quantitative DNA analysis. Cells were cultured on 
smooth (PT) or rough (SLA) Ti surfaces in the presence or absence of serotonin or other categories 
of antidepressants within the SSRI or SNRI class. Additional types of commonly prescribed 
antidepressants that are not selective for serotonin were used for comparison. Serotonin treatment 
was used as the positive control. Effects of serotonin or antidepressants were compared to cells 
cultured in media not containing any treatment. Treatment concentrations of 1µM or 10µM were 
chosen. The lower concentration is representative of therapeutic levels present in the blood for 
patients taking SSRIs. Since SSRIs are known to sequester in the bone marrow at concentrations 
much higher than those in the brain or blood, treatment with the 10µM concentration is intended 
to represent these conditions. 
Serotonin 
In the no treatment groups for all experiments, DNA content was significantly lower in 
human MSCs cultured on SLA surfaces, but not different on PT, in comparison to TCPS (figure 
8). Treatment with 1µM of serotonin significantly increased DNA content in comparison to the no 
treatment groups on TCPS and PT surfaces (figure 8a). There was no difference between serotonin 
treatment and the no treatment control on SLA surfaces. 
SSRIS 
Cells were grown in the presence on fluoxetine, sertraline or paroxetine. Similar to 
serotonin, treatment with 1µM of fluoxetine also increased DNA content in comparison to the no 
treatment groups on TCPS and PT. Treatment with 10µM decreased it in comparison to the no 
treatment control (figure 8b). There was no difference between the 1µM and the control on SLA, 
however, treatment with 10µM showed the most significant decreases in DNA content in 




There was no difference between the control and the 1µM concentration of sertraline on 
TCPS and PT, however, increasing the concentration to 10µM significantly decreased DNA 
content in comparison to the control (figure 8c). There was no difference between sertraline 
treatments and the no treatment control on SLA surfaces. 
Paroxetine treatment at 1µM concentration had no significant difference when compared 
with the no treatment control on TCPS and PT (figure 8d), however, increasing the concentration 
to 10µM significantly decreased DNA content in comparison to the no treatment control. On SLA 
surfaces, paroxetine treatment dose-dependently decreased DNA content in comparison to the no 
treatment control, with the 10µM concentration having the most significant decreases in DNA 
content in comparison with TCPS, PT and the 1µM concentration. 
a) b) 
c) d) 
Figure 8: Human MSC DNA content after treatment with serotonin or SSRIs. Cells were treated with 1μM or 
10μM concentrations of a) serotonin, b) fluoxetine, c) sertraline or d) paroxetine and cultured on TCPS, PT or SLA 





Duloxetine, an SNRI, had no difference in DNA content between the no treatment control 
and the 1µM concentration on TCPS and PT surfaces (Figure 9). Increasing the dose to 10µM 
significantly decreased DNA content on TCPS in comparison to the no treatment control and the 
1µM concentration, with further decreases on PT surfaces. There was no difference in DNA 
content on SLA surfaces after duloxetine treatment in comparison to the no treatment control.  
Other Antidepressants 
Trazodone was similar to duloxetine in that there was no significant difference between the 
no treatment control and the 1µM concentration on TCPS and PT surfaces, but treatment with 
10µM significantly decreased DNA content on TCPS, with further decreases on PT (figure 10a). 
DNA content was lower on all SLA surfaces in comparison to TCPS and PT, however, no 
significant differences were apparent between treatment and no treatment controls. 
There was no difference in DNA content after treatment with bupropion in comparison to 
the no treatment control on TCPS (figure 10b). Treatment with 1µM and 10µM concentrations of 
bupropion decreased DNA content in comparison to the no treatment control on PT, with further 
decreases on SLA surfaces, however, there were no significant differences between each dose. 
Figure 9: Human MSC DNA content after treatment with an SNRI. Cells were treated with 1μM or 10μM 
concentrations of duloxetine and cultured on TCPS, PT or SLA surfaces. P < 0.05 # vs. TCPS, $ vs. PT. P < 0.05 




3.1.1. AIM 1.1: DETERMINE THE EFFECTS OF ANTIDEPRESSANT TREATMENTS 
ON HUMAN MSC DIFFERENTIATION WHILE CULTURED ON SMOOTH VS. 
ROUGH Ti SURFACES 
To determine the effects of antidepressant treatment on bone formation and dental implant 
osseointegration, MSC differentiation potential was assessed on Ti substrates. Cells were cultured 
on smooth (PT) or rough (SLA) Ti substrates and compared to those on TCPS during treatments 
of either serotonin or antidepressants. MSC differentiation was measured by analyzing alkaline 
phosphatase specific activity as an early marker of osteoblastic differentiation, and OCN protein 
levels as a late marker. The hypothesis is antidepressant treatment will prevent human MSC 
differentiation, which can lead to delayed osseointegration. 
 Effects of Serotonin on MSC Differentiation 
Alkaline phosphatase activity was highest prior to any treatment with serotonin in human 
MSCs plated on SLA surfaces when compared to TCPS and PT (figure 11a). There was no 
significant difference in enzyme activity after treatment with 1μM in comparison to the no 
treatment control. Enzyme activity increased with the addition of serotonin at the 10μM 
concentration in comparison with the 1μM treatment on TCPS and with further increases on PT 
surfaces, in comparison to the no treatment control. On SLA surfaces, however, this effect was 
reversed. Serotonin treatment dose-dependently decreased enzymatic activity, with the lowest 
levels evident at the 10μM concentration in comparison to the no treatment control. 
a) b) 
Figure 10: Human MSC DNA content after treatment with other types of antidepressants. Cells were treated 
with 1μM or 10μM concentrations of a) trazodone or b) bupropion and cultured on TCPS, PT or SLA surfaces. P < 




The effect of serotonin on late osteoblastic differentiation was assessed by measuring 
secreted levels of OCN by human MSCs throughout differentiation. Prior to any treatments, levels 
of OCN increased with the increasing surfaces roughness, with the highest increases evident on 
SLA (figure 11b). Treatment with 1μM of serotonin significantly decreased OCN protein levels 
on all surfaces in comparison to their no treatment controls. This effect was rescued when the dose 
was augmented to 10μM, however. Protein levels were higher on TCPS, with further increases on 
PT surfaces, in comparison to their no treatment controls. All serotonin treatments decreased OCN 
protein levels on SLA surfaces in comparison to the no treatment control, with the most decreases 
at the 1μM concentration. 
Effects of SSRIs on MSC Differentiation 
Effects of SSRIs fluoxetine, sertraline and paroxetine on early human MSC differentiation 
were assessed by measuring enzymatic activity for alkaline phosphatase. Enzymatic activity was 
highest prior to treatment with antidepressants in human MSCs plated on SLA surfaces when 
compared to TCPS and PT (figures 12, 13, 14, 15, 16 and 17). In general, treatment with all types 
of SSRIs decreased alkaline phosphatase activity in a dose-dependent manor on SLA surfaces, 
with the lowest levels evident at the 10μM concentration, in comparison to the no treatment control 
(figures 12, 13 and 14). Fluoxetine treatment did not affect enzymatic activity on TCPS in 
comparison to the no treatment control (figure 12a). Only the 10μM dose decreased enzyme 
activity when compared with the lower dose on PT surfaces and TCPS. Treatment with 1μM 
Figure 11: Effects of serotonin on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of serotonin on 




concentrations of fluoxetine decreased OCN protein levels on all surfaces in comparison to the no 
treatment control (figure 12b). The 10μM treatment increased levels on TCPS and PT when 
compared with the 1μM dose, but was not statistically significant against the no treatment control. 
All concentrations of fluoxetine decreased OCN protein levels on SLA surfaces in comparison to 
the no treatment control, with the lowest decreases seen after treatment with the 1μM 
concentration. 
Alkaline phosphatase activity was lowest after treatment with 10μM concentration of 
sertraline on TCPS and PT surfaces in comparison to the 1μM concentration and their no treatment 
control (figure 13a). There was no difference in enzymatic activity between the 1μM and 10μM 
treatments on TCPS and PT surfaces. Both 1μM and 10μM sertraline treatments decreased OCN 
protein levels on TCPS in comparison to the no treatment control (figure 13b). Sertraline effects 
were more robust on Ti surfaces, as evident by the significantly lower decreases, in a dose-
dependent manor, in protein levels on PT and SLA surfaces. 
Paroxetine treatment at the 10μM concentration decreased alkaline phosphatase activity on 
TCPS in comparison to the 1μM concentration, but was not statistically significant when compared 
to its no treatment control (figure 14a). Treatment with the 1μM concentration increased enzymatic 
activity in comparison to the no treatment control, however, when the dose was augmented to 
10μM, activity decreased in comparison to the 1μM on PT surfaces. There was no difference 
Figure 12: Effects of SSRI fluoxetine on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase specific activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of 





between paroxetine treatments on OCN protein levels on TCPS and PT in comparison to the no 
treatment control (figure 14b), though, both concentrations equally decreased levels on SLA 
surfaces in comparison to the no treatment control. 
Effects of SNRIs on MSC Differentiation 
To determine how SNRIs affect human MSC differentiation in comparison to SSRIs and 
serotonin, MSCs were treated with duloxetine at the same doses and early and late differentiation 
was assessed. There was no statistical difference in enzymatic activity between duloxetine 
Figure 13: Effects of SSRI sertraline on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of sertraline on 
TCPS, PT or SLA surfaces. P < 0.05 # vs. TCPS, $ vs. PT. P < 0.05 a vs. 0µM, b vs. 1µM. 
Figure 14: Effects of SSRI paroxetine on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of paroxetine 




treatments at either concentration on TCPS or PT surfaces in comparison to the no treatment 
control (figure 15a). On SLA, there was no statistical difference between the 1μM concentration 
and the no treatment control, yet both were higher than levels on TCPS and PT surfaces. There 
was also no difference between the 1μM and 10μM concentrations on SLA, but the 10μM 
concentration decreased activity the most in comparison to the no treatment control. Treatment 
with 1μM concentration of duloxetine decreased OCN protein levels on all surfaces in comparison 
to the no treatment control (figure 15b). Raising the dose to 10μM increased protein levels in 
comparison to the 1μM dose on Ti surfaces in comparison to TCPS, with the most increases seen 
on SLA.  
Effects of Other Antidepressants on MSC Differentiation 
Trazodone and bupropion are two antidepressants that do not belong to a specific category. 
Their effects on cell differentiation was also compared with serotonin and other types of 
antidepressants. There was no significant difference between both, trazodone and bupropion 
treatments, on alkaline phosphatase activity for human MSCs cultured on TCPS surfaces (figures 
16a and 17a). Only the 10μM concentration of trazodone decreased enzymatic activity on PT in 
comparison to the no treatment control (figure 16a), but no differences were evident with either 
bupropion treatments on the same surfaces (figure 17b). Trazodone treatment dose-dependently 
decreased enzyme activity on SLA surfaces in comparison to the no treatment control, with the 
most significant decreases seen after treatment with the 10μM concentration (figure 16a). There 
Figure 15: Effects of SNRI duloxetine on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of duloxetine 




was no significant difference between the 1μM dose of bupropion and the no treatment control on 
SLA surfaces, however, the 10μM concentration decreased enzyme activity in comparison to the 
1μM concentration and the no treatment control (figure 17b). 
Both Trazodone and bupropion treatments were similar in that they had no significant 
effects on OCN protein levels in comparison to the no treatment controls on TCPS surfaces (figures 
16b and 17b). On PT surfaces, treatment with 1μM of trazodone slightly increased protein levels 
in comparison to the same concentration on TCPS, but this effect was not statistically significant 
Figure 16: Effects of trazodone on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of trazodone on 
TCPS, PT or SLA surfaces. P < 0.05 # vs. TCPS, $ vs. PT. P < 0.05 a vs. 0µM, b vs. 1µM. 
a) b) 
Figure 17: Effects of bupropion on early and late osteoblastic differentiation. Human MSC a) alkaline 
phosphatase activity and b) OCN protein levels after treatment with 1μM or 10μM concentrations of bupropion on 




when compared to its no treatment control (figure 16a). Increasing the trazodone dose to 10μM on 
PT, however, decreased protein levels in comparison to the 1μM concentration and the no 
treatment control. Only the 1μM treatment of bupropion increased protein levels on PT surfaces 
in comparison to the 10μM and the no treatment control (figure 16b). On SLA surfaces, both 
trazodone and bupropion treatments dose-dependently decreased OCN protein levels in 
comparison to TCPS and PT, with the highest concentrations having the lowest amount of protein 
(figures 16b and 17b). Overall, decreases in early and late differentiation markers were 
significantly less robust with treatments of serotonin or any type of antidepressant on TCPS or PT 
surfaces in comparison to SLA. 
Antidepressants and Ti Surface Characteristics Modulate Gene Expression of Osteoblastic 
Differentiation Markers 
For further investigation of the effects of antidepressants on bone formation, human MSC 
gene expression of early and late osteoblastic differentiation markers were assessed on various Ti 
surfaces. The effects of surface roughness and wettability on osteoblastic gene expression were 
assessed first, prior to addition of antidepressant or serotonin treatment. mRNA expression levels 
of genes important for early (RUNX2) and late (BGLAP) bone development for human MSCs 
were assessed by qPCR. Cells were grown on smooth and hydrophobic (PT), rough and 
hydrophobic (SLA), or rough and hydrophilic (mSLA) Ti surfaces, throughout differentiation and 
compared with cells on TCPS as the control. Expression of RUNX2 and BGLAP increased on Ti 
Figure 18: Surface characteristics effects on osteoblastic gene expression. Human MSC mRNA levels for 




substrates in comparison to TCPS, with the highest increases evident on rough and rough and 
hydrophilic substrates (figure 18). There were no significant differences in mRNA levels between 
rough (SLA) and rough and hydrophilic (mSLA) substrates. 
Effects of Serotonin and Surface Characteristics on Osteoblastic Gene Expression 
Once the surface characteristics effects on gene expression were established, effects of 
antidepressants were assessed. In order to determine the effects of serotonin on bone formation on 
Ti surfaces, mRNA expression levels of RUNX2 and BGLAP for human MSCs were assessed by 
qPCR after treatment with 0.1μM, 1μM or 10μM concentrations of serotonin. Since no differences 
in mRNA levels for osteoblastic differentiation markers were seen in MSCs cultured on 
hydrophilic (mSLA) vs. hydrophobic (SLA) rough substrates, cells were grown on smooth (PT) 
or rough (SLA) Ti surfaces for the remainder studies to compare the effects of rough vs. smooth 
substrates on differentiation in the presence of serotonin. As previously shown, higher levels of 
early osteoblastic differentiation marker and transcription factor, RUNX2, and late marker, 
BGLAP, were evident on PT with further increases on SLA surfaces in comparison with TCPS 
prior to serotonin treatment (figure 19).  
Treatment with serotonin increased mRNA levels on TCPS in comparison to the no 
treatment control, with the highest levels seen after treatment with the 1μM concentration (figure 
19a). Only the highest concentration, 10μM, on PT surfaces showed significant increases in mRNA 
a) b) 
TCPS PT SLA TCPS PT SLA 
Figure 19: Effects of serotonin on gene expression for osteoblastic differentiation. Human MSC mRNA levels 
for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM concentrations of serotonin, cultured 
on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 a vs. 0µM, 




levels in comparison to the lower concentrations and the no treatment control. On SLA surfaces, 
however, all serotonin treatments decreased RUNX2 mRNA levels in comparison to the no 
treatment control, with the most significant decreases apparent after treatment with the 10μM 
concentration. 
Serotonin treatment at all concentrations increased mRNA levels for the late osteoblastic 
differentiation marker, BGLAP, on TCPS and PT surfaces in comparison to their no treatment 
control (figure 19b). The highest expression was apparent after treatment with the 1μM 
concentration, while the lowest was after 10μM on both TCPS and PT surfaces. On SLA surfaces, 
however, this effect was reversed. Serotonin treatments dose-dependently decreased mRNA levels 
in comparison to the no treatment control, with the 10μM concentration having the lowest levels. 
Effects of SSRIs and Surface Characteristics on Osteoblastic Gene Expression 
To determine how MSC differentiation is affected under fluoxetine, sertraline or paroxetine 
exposure in comparison to serotonin on Ti surfaces, mRNA levels for the same early and late 
osteoblastic differentiation markers were assessed. Prior to any SSRI treatment, RUNX2 and 
BGLAP expression increased on PT surfaces, with further increases on SLA (figures 20, 21 and 
22). There was no difference between levels of RUNX2 mRNA after treatment with all 
concentrations of fluoxetine in comparison to the no treatment control on TCPS (figure 20a). Only 
the 10μM concentration decreased mRNA levels when compared with the no treatment control on 
a) b) 
Figure 20: SSRI fluoxetine inhibits gene expression for osteoblastic differentiation on microstructured Ti. 
Human MSC mRNA levels for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM 
concentrations of fluoxetine, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ 




PT surfaces. In a similar manor, mRNA levels for BGLAP were only slightly elevated after 
treatment with the 0.1μM concentration of fluoxetine on TCPS in comparison to the no treatment 
control (figure 20b). On PT surfaces, the 1μM and 10μM concentrations decreased mRNA levels 
in comparison to the no treatment control. However, mRNA levels for both RUNX2 and BGLAP 
displayed the same dose-dependent response on SLA surfaces, where all concentrations of 
fluoxetine decreased levels, with the most significant decreases evident at the highest 
concentration of 10μM when compared with the no treatment control. 
Since treatment with the 1μM and 10μM concentrations of serotonin or fluoxetine 
exhibited the most statistically significant changes in mRNA levels for markers of differentiation, 
they were the concentrations of choice and were used for the remaining osteoblastic differentiation 
assessments. Sertraline treatment had no effect on mRNA levels for BGLAP, and only slightly 
decreased levels at the 10μM concentration for RUNX2 levels on TCPS surfaces in comparison to 
the no treatment control (figure 21). On Ti surfaces, however, effects were more robust. Sertraline 
treatment exhibited dose-dependent decreases in RUNX2 and BGLAP mRNA levels on Ti 
surfaces in comparison to TCPS, with the 10μM concentration having the most significant 
decreases. Dose-dependency effects on mRNA levels for both RUNX2 and BGLAP were more 
robust on rough (SLA) Ti surfaces in comparison to smooth (PT) and TCPS, with the 10μM 
a) b) 
TCPS PT SLA TCPS PT SLA 
Figure 21: SSRI sertraline inhibits gene expression for osteoblastic differentiation on microstructured Ti. 
Human MSC mRNA levels for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM 
concentrations of fluoxetine, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ 




concentration having the most significant decreases on SLA in comparison to all treatment and no 
treatment groups. 
Paroxetine increased mRNA levels for BGLAP on TCPS, and at the 10μM concentration 
for RUNX2, when compared to the no treatment control (figure 22a and b). This effect was 
reversed, however, on Ti substrates. Treatment with paroxetine decreased levels for RUNX2 and 
BGLAP on PT and SLA surfaces in comparison to the no treatment control, with the lowest 
decreases evident after treatment with the 1μM concentration. Levels were higher when the 
concentration was increased to 10μM in comparison to the 1μM treatment, but were still 
significantly lower than the no treatment control. 
SNRI and Surface Characteristics Effects on Osteoblastic Gene Expression 
Duloxetine treatment had no significant effect on RUNX2 or BGLAP mRNA levels on 
TCPS in comparison to the no treatment control (figure 23a and b). However, significant 
differences were evident with the same treatment on microstructured Ti substrates. Treatment with 
duloxetine dose-dependently decreased levels of early (RUNX2) and late (BGLAP) osteoblastic 
differentiation markers on PT and SLA surfaces in comparison to the no treatment control, with 
the lowest levels evident after treatment with the highest concentration of the drug. 
Other Antidepressant and Surface Characteristics Effects on Osteoblastic Gene Expression 
a) b) 
TCPS PT SLA TCPS PT SLA 
Figure 22: SSRI paroxetine inhibits gene expression for osteoblastic differentiation on microstructured Ti. 
Human MSC mRNA levels for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM 
concentrations of fluoxetine, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ 




Trazodone and bupropion treatment had no effect on mRNA levels for RUNX2 or BGLAP 
on TCPS in comparison to the no treatment control (figures 24 and 25). Treatment with trazodone 
and bupropion decreased levels of RUNX2 on PT surfaces in comparison to the no treatment 
control, with further decreases after treatment with 10µM of bupropion (figures 24a and 25a). 
There was no significant difference in RUNX2 levels between each trazodone dose (figure 24a). 
There was a dose-dependent decrease for levels of BGLAP on PT surfaces, with the lowest levels 
evident after treatment with the highest concentration of trazodone (figure 24b). Bupropion also 
a) b) 
TCPS PT SLA TCPS PT SLA 
Figure 23: SNRI duloxetine inhibits gene expression for osteoblastic differentiation on microstructured Ti. 
Human MSC mRNA levels for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM 
concentrations of fluoxetine, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ 
vs. PT. Per surface: P < 0.05 a vs. 0µM, b vs. 0.1 µM, c vs. 1µM. 
a) b) 
TCPS PT SLA TCPS PT SLA 
Figure 24: Trazodone inhibits gene expression for osteoblastic differentiation on microstructured Ti. Human 
MSC mRNA levels for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM concentrations of 
fluoxetine, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: 




decreased BGLAP levels on PT surfaces in comparison to the no treatment control, however with 
no significant difference in levels between each dose (figure 24b). Both trazodone and bupropion 
dose-dependently decreased RUNX2 and BGLAP mRNA levels on SLA surfaces in comparison 
to the no treatment control, with the lowest levels evident after treatment with the highest 
concentration of drug (figures 24b and 25b). 
3.1.2. AIM 1.2: DETERMINE THE EEFFECTS OF ANTIDEPRESSANT 
TREATMENTS ON HUMAN MSC LOCAL FACTOR PRODCUTION OF BMP2, 
OPG, RANKL AND VEGF PROTEIN LEVELS IN THE MICROENVIRONMENT 
ON Ti SURFACES 
In order to determine if antidepressant treatment has an effect on local factor production of 
important proteins in the microenvironment generated by human MSCs while cultured on Ti 
surfaces, cells were cultured on smooth or rough Ti surfaces and treated with various types of 
antidepressants. Cells were treated with 1μM or 10μM of serotonin, SSRIs (fluoxetine, sertraline 
or paroxetine), SNRIs (duloxetine), or other antidepressants (trazodone or bupropion). Treated 
cells were compared to the no treatment controls on each surface. To assess the effects of 
treatments on the microenvironment, secreted protein levels for BMP2, VEGF, OPG and RANKL 
were measured. 
Serotonin Effects on the Microenvironment 
a) b) 
TCPS PT SLA TCPS PT SLA 
Figure 25: Bupropion inhibits gene expression for osteoblastic differentiation on microstructured Ti. Human 
MSC mRNA levels for RUNX2 and BGLAP after treatment with 0μM, 0.1μM, 1μM or 10μM concentrations of 
fluoxetine, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: 




Local factor production by human MSCs was assessed after treatment with 1μM or 10μM 
concentrations of serotonin. Human MSC protein levels for BMP2, VEGF and OPG all increased 
prior to any serotonin treatment on PT surfaces, with further increases on SLA, in comparison to 
TCPS (figure 26a, b and c). Treatment with serotonin had no significant effect on secreted BMP-
2 levels on TCPS, however, all concentrations of serotonin decreased protein levels on PT and 
SLA surfaces in comparison to the no treatment control, with no significant differences between 
the 1μM and 10μM concentrations (figure 26a). Only the 10μM concentration of serotonin 
decreased VEGF protein levels on TCPS in comparison to the no treatment control, while the 1μM 
concentration had no significant effect (figure 26b). Both 1μM and 10μM treatments of serotonin 
decreased VEGF protein levels on PT and SLA surfaces in comparison to the no treatment control. 
No significant differences in protein levels were detected between the 1μM and 10μM 
Figure 26: Effects of serotonin on MSC protein production. Human MSC protein levels for a) 
BMP2, b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of 
serotonin, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. 




concentration treatments on Ti surfaces. OPG protein levels increased after treatment with 1μM 
concentration of serotonin on TCPS in comparison with the no treatment control (figure 26c) and 
increasing the dose to 10μM decreased levels in comparison to the 1μM concentration, though 
with no significance difference when compared with the no treatment control. Serotonin treatment 
dose-dependently decreased OPG levels on PT in comparison to the no treatment control, with 
further decreases on SLA surfaces, in comparison to TCPS. The 10μM concentration seemed to 
have the more decreases in protein levels, with the most decreases evident on SLA surfaces. 
RANKL protein levels decreased after treatment with 1μM of serotonin on all surfaces in 
comparison with the no treatment control (figure 26d). Augmenting the concentration to 10μM 
slightly increased levels when compared with the 1μM concentration, but this effect was not 
statistically significant when compared with the no treatment control. 
SSRI Effects on the Microenvironment 
Effects of SSRI treatment on local factor protein production by human MSCs while 
plated on Ti surfaces was assessed after treatments with fluoxetine, sertraline or paroxetine at 
1μM or 10μM concentrations. All protein levels secreted by human MSCs increased on Ti 
surfaces in comparison to TCPS prior to SSRI treatment (figures 25, 26 and 27). There was no 
difference in BMP2 protein levels after treatment with fluoxetine on TCPS when compared with 
the no treatment control, but on Ti surfaces, however, fluoxetine decreased protein levels in 
comparison to the no treatment control (figure 25a). There was no difference in BMP-2 levels 
between treatments with 1μM or 10μM concentrations on PT surfaces. Differences in doses was 
apparent on SLA surfaces, as fluoxetine exhibited a dose-dependent decrease in secreted protein 
levels, with the lowest levels evident after treatment with the 10μM concentrations in 




Fluoxetine treatment had no significant effect on secreted VEGF protein levels when 
compared to the no treatment control on TCPS and PT surfaces (figure 27b). Augmenting the 
dose to 10μM slightly increased protein levels compared to the 1μM concentration, but was still 
statistically insignificant when compared to the no treatment control. On SLA surfaces, 1μM and 
10μM of fluoxetine decreased protein levels in comparison to the no treatment control. Effects of 
treating with the 10μM dose seemed to be slightly stimulatory in terms of protein secretion when 
compared to the 1μM dose. 
There was no significant effect on OPG protein levels when treated with fluoxetine on 
TCPS in comparison to the no treatment control (Figure 27c). Fluoxetine dose-dependently 
decreased protein levels on PT and SLA surfaces in comparison to their no treatment controls, 
with the most significant decreases apparent after treatment with the 10μM concentration. There 
Figure 27: Effects of SSRI fluoxetine on MSC protein production. Human MSC protein levels for a) 
BMP-2, b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of 
serotonin, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per 




was no difference in RANKL protein levels after 1μM of fluoxetine on TCPS and PT surfaces 
(figure 27d). The 10μM concentration slightly increased levels compared to the 1μM concentration 
on TCPS, with further increases on PT in comparison to the 1μM and the no treatment control. On 
SLA surfaces, fluoxetine decreased RANKL protein levels at the 1μM concentration compared to 
the no treatment control, but levels significantly increased after treatment with 10μM in 
comparison to TCPS, PT, 1μM and the no treatment control. 
Sertraline treatment decreased BMP2 protein levels on all surfaces in comparison to the no 
treatment control (figure 28a). There was no significant difference in protein levels between the 
1μM concentration and the no treatment on TCPS, however, augmenting the dose to 10μM 
significantly decreased levels in comparison to the 1μM and the no treatment control. Treatment 
with sertraline dose-dependently decreased protein levels on PT and SLA surface in comparison 
to the no treatment control, with the most significant decreases seen after treatment with the 10μM 
concentration. Dose-dependent decreases in VEGF protein levels were evident on all surfaces, 
with the lowest levels evident after treatment with the 10μM concentration of sertraline (figure 
28b). 
There was no difference in OPG protein levels between the 1μM dose and the no treatment 
control on TCPS, however, the 10μM concentration of sertraline significantly decreased levels 
(figure 28c). On PT surfaces, slight decreases in protein levels were detected after treatment with 
the 1μM concentration, with further decreases after the 10μM dose in compared to the no treatment 
control. The 1μM dose significantly decreased protein levels on SLA surfaces when compared 
with the no treatment control and protein levels actually failed to be detected after treatment with 
the 10μM dose of sertraline. 
All treatments of sertraline increased RANKL production on TCPS, with further increases 
on Ti surfaces, when compared with the no treatment control (figure 28d). There was no difference 
in RANKL protein levels between the 1μM and the 10μM dose on TCPS in comparison to no 
treatment. On PT surfaces, augmenting the dose to 10μM further increased RANKL protein levels 
in comparison to the no treatment and the 1μM concentration. Treatment with 10μM of sertraline 




highest levels were evident after treatment with the 1μM dose when compared to the 10μM dose, 
TCPS and PT surfaces. 
 Paroxetine dose-dependently decreased BMP2 and VEGF protein levels on TCPS, PT and 
SLA surfaces in comparison to the no treatment control, with the lowest levels evident after 
treatment with the 10μM concentration (figure 29a and b). There was no difference in OPG protein 
levels between the 1μM concentration and no treatment control on TCPS and PT surfaces, but the 
10μM dose significantly decreased levels when compared to the 1μM and no treatment control 
(figure 29c). Dose-dependent decreases in protein levels on SLA surfaces were evident with 
paroxetine treatment, with the lowest levels apparent with 10μM concentration treatments. 
Paroxetine slightly increased RANKL protein levels on TCPS and PT in comparison to the no 
treatment control, with no significant differences in levels after treatment with either the 1μM or 
Figure 28: Effects of SSRI sertraline on MSC protein production. Human MSC protein levels for a) 
BMP2, b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of 
serotonin, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per 




the 10μM dose (figure 29d). On SLA surfaces, however, both doses significantly increased 
RANKL production compared to no treatment, with the 1μM concentration having the highest 
protein levels in comparison to TCPS, PT, the 10μM concentration and the no treatment control. 
SNRI Effects on the Microenvironment 
 Effects of SNRIs on the microenvironment production by MSC was assessed in in a similar 
manner as the SSRIs and serotonin. Antidepressants within the SNRI class are not only selective 
for serotonin, as they modulate levels of norepinephrine as well. MSCs were plated on PT or SLA 
surfaces and compared to those on TCPS after treatments with 1μM or 10μM concentrations of 
the SNRI duloxetine. All protein levels secreted by human MSCs increased on Ti surfaces in 
comparison to TCPS prior to SNRI treatment (figures 30). Treatment with duloxetine dose-
dependently decreased BMP2 and VEGF protein levels on TCPS, PT and SLA surfaces in 
comparison to the no treatment control, with the lowest protein levels evident after treatment with 
Figure 29: Effects of SSRI paroxetine on MSC protein production. Human MSC protein levels for a) 
BMP2, b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of 
serotonin, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per 




the 10μM concentration (figure 30a and b). There was no significant difference in OPG protein 
levels between treatments with the 1μM concentration of duloxetine and the no treatment control 
on TCPS and PT surfaces (figure 30c). However, increasing the dose to 10μM decreased protein 
levels on TCPS when compared to the no treatment control, with further decreases in comparison 
to the 1μM and the no treatment control on PT. Dose-dependent decreases in protein levels were 
evident on SLA surfaces, with the lowest levels of protein after treatment with the 10μM 
concentration in comparison to the 1μM concentration and the no treatment control. Treatment 
with 10μM of duloxetine increased RANKL protein levels on TCPS and PT surfaces in comparison 
to the no treatment control, while the 1μM had no significant effects (figure 30d). On SLA, does-
dependent increases in protein levels were apparent, with the highest levels seen after treatment 
with the 10μM concentration. 
Other Antidepressant Effects on the Microenvironment 
Figure 30: Effects of SNRI duloxetine on MSC protein production. Human MSC protein levels for a) 
BMP2, b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of 
serotonin, cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per 




Trazodone and bupropion are commonly prescribed antidepressants that do not belong to 
a specific class. Their effects on microenvironment production by MSC on Ti surfaces was also 
assessed. All protein levels secreted by human MSCs increased on Ti surfaces in comparison to 
TCPS prior to any antidepressant treatment (figures 31 and 32). Addition of trazodone decreased 
BMP2, VEGF and OPG protein levels and increased RANKL levels on all surfaces (figure 31).  
There was no difference in BMP2 and VEGF protein levels after treatment with 1µM of 
trazodone on TCPS surfaces in comparison to the no treatment control and increasing this 
concentration to 10µM decreased protein levels when compared to the 1µM and the no treatment 
control (figures 31a and b). Dose-dependent decreases in BMP2 protein levels were more evident 
on PT and SLA surfaces as trazodone concentrations increased (figure 31a). A similar effect was 
seen for VEGF as levels were even lower on Ti surfaces in comparison with no treatment (figure 
31b). VEGF levels were lower on PT surfaces in comparison to TCPS, and further decreases on 
Figure 31: Effects of trazodone on MSC protein production. Human MSC protein levels for a) BMP-2, 
b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of serotonin, 
cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 




SLA surfaces. There were no significant differences between the 1µM concentration and the no 
treatment control, but treatment with 10µM of trazodone decreased OPG protein levels on TCPS 
in comparison to the control (figure 31c). Trazodone treatment at 10µM concentrations dose-
dependently decreased OPG levels on PT, with further decreases on SLA, when compared to the 
1µM concentration and the no treatment control. The opposite effect was true for RANKL protein 
levels, as trazodone dose-dependently increased secreted levels with the incremental increases in 
concentrations on all surfaces when compared to the no treatment control (figure 31d). Protein 
levels were higher as trazodone concentrations increased on Ti surfaces in comparison to TCPS. 
Treatment with bupropion does-dependently decreased BMP2 protein levels on PT and 
SLA surfaces in comparison to the no treatment control, with the 10µM concentration having the 
lowest levels (figure 30a). Only the 10µM dose decreased levels on TCPS in comparison to the 
a) b) 
c) d) 
Figure 32: Effects of bupropion on MSC protein production. Human MSC protein levels for a) BMP2, 
b) VEGF, c) OPG and d) RANKL after treatment with 0μM, 1μM or 10μM concentrations of serotonin, 
cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 




1µM and no treatment control. Treatment decreased VEGF levels on all surfaces in comparison to 
the control, with no difference in levels between concentrations on TCPS (figure30b). Bupropion 
treatment had no effect on OPG protein levels in comparison to the no treatment control on TCPS 
or PT surfaces (figure 30c). Treatment decreased levels on SLA surfaces in comparison to the no 
treatment control, with no significant difference in levels between the 1μM or 10μM 
concentrations. Both concentrations of bupropion increased RANKL protein levels on TCPS and 
PT surfaces in comparison to the no treatment control, with no significant differences in levels 
between each dose (figure 30d). Dose-dependent increases in RANKL levels were evident on SLA 
surfaces in comparison to the no treatment control, with the greatest levels seen after treatment 
with the 10µM concentration when compared with TCPS, PT, the 1µM concentration and the no 
treatment control. 
3.2. SPECIFIC AIM 2: DETERMINE THE EFFECTS OF ANTIDEPRESSANTS ON 
BONE REMODELING SIGNALING AND OSTEOCLAST ACTIVATION 
Results from aim 2 assess the effects of antidepressants on MSC production of the local 
microenvironment and how this can affect osteoclastic activity. Osteoclast precursors were treated 
with MCS-F (20ng/mL) and RANKL (50ng/mL) and exposed to various types and concentrations 
of antidepressants or serotonin, either directly or through conditioned media from human MSCs 
which were treated with antidepressants. Osteoclastic behavior was assessed by measuring TRAP 
activity. 
3.2.1. AIM 2.1: DETERMINE THE DIRECT EFFECTS OF ANTIDEPRESSANTS ON 
OSTEOCLASTIC ACTIVITY 
In order to determine the direct effects of SSRIs on osteoclastic TRAP activity in 
comparison to other antidepressants with lower selectivity for serotonin, SSRI fluoxetine was 
selected, as well as SNRI duloxetine were used for treatments and compared to treatment of 
serotonin. There was no difference in osteoclastic TRAP activity between 1µM treatments of 
serotonin and fluoxetine in comparison to the no treatment control (figure 33). However, treatment 
with a higher concentration of 10µM increased TRAP activity in comparison to the 1µM dose and 




control, however, activity significantly decreased when cells were treated with 10µM 
concentrations in comparison to the control.  
3.2.2. AIM 2.2: DETERMINE THE EFFECTS OF CONDITIONED MEDIA FROM 
MSCs TREATED WITH ANTIDEPRESSANTS ON OSTEOCLASTIC ACTIVITY 
In order to further investigate if exposing osteoclasts to the microenvironment generated 
by MSCs after their treatment with antidepressants has the potential to affect TRAP activity, 
osteoclasts were treated with conditioned media obtained from MSCs cultured on Ti surfaces. 
Surface roughness effects on MSC microenvironment production during antidepressant treatments 
on TRAP activity were also assessed. MSCs were plated on TCPS, PT or SLA surfaces and treated 
with 1µM or 10µM concentrations of serotonin, fluoxetine, sertraline or duloxetine. After 
treatment, the conditioned media was collected and used to treat osteoclasts for 48 hours and TRAP 
activity was measured to determine osteoclastic activity. 
In conditioned media obtained from MSCs not exposed to antidepressants or serotonin 
(control media), TRAP activity increased on Ti surfaces in comparison to TCPS, with no 
difference in activity between smooth or rough Ti surfaces (figure 34a, b and c). Overall, 
Figure 33: Direct effects of antidepressants on osteoclastic TRAP activity.  MCS-F and RANKL-differentiated 
human monocytes were directly exposed to serotonin, SSRI fluoxetine and SNRI duloxetine at concentrations of 




antidepressants and serotonin conditioned media increased osteoclastic TRAP activity on all 
surfaces, with the most significant increases evident on SLA. Serotonin and fluoxetine conditioned 
media increased TRAP activity on TCPS only at the 10µM concentration, with no significant 
increases on PT surfaces, in comparison to the control (figure 34a and b). On SLA surfaces, 
however, serotonin and fluoxetine conditioned media dose-dependently increased TRAP activity, 
with the highest levels after treatment with 10µM of conditioned media when compared to TCPS, 
PT, 1µM and the control. Conditioned media obtained from MSCs treated with duloxetine from 
all surfaces increased TRAP activity when compared with the control (figure 34c). Activity was 
highest for media obtained from the 10µM duloxetine treatments on PT and SLA surfaces in 
comparison to the control. 
3.3. SPECIFIC AIM 3: ELUCIDATE THE EFFECTS OF SSRIS ON SEROTONIN 
RECEPTORS AND THEIR EFFECTS ON BONE REMODELING 
Figure 34: Effects of conditioned media on osteoclastic TRAP activity. MCS-F and RANKL-differentiated 
monocytes were exposed to conditioned media from MSCs treated with concentrations of 1μM or 10μM of a) 
serotonin, b) fluoxetine, and c) duloxetine while cultured on TCPS, PT or SLA surfaces. Between surfaces: P < 




Antidepressants exhibit their therapeutic effects in vivo by blocking 5-HTT and increasing 
extracellular concentrations of serotonin. Serotonin then interacts with its various receptors found 
on cells, initiating complex internal signal transduction pathways involved in gene expression. The 
goal for this aim is to determine how surface characteristics of Ti implants affect human MSC 
gene expression of serotonin receptors when cultured on microstructured Ti surfaces. Human 
MSCs were grown on smooth (PT), rough (SLA) or rough and hydrophilic (mSLA) Ti substrates 
throughout differentiation and mRNA levels for HTR1A, HTR2A, HTR1B and HTR2B were 
measured for using qPCR. 
3.3.1. AIM 3.1: DETERMINE THE EFFECTS OF TI SURFACE ROUGHNESS AND 
WETTABILITY ON HUMAN MSC SEROTONIN RECEPTOR GENE 
EXPRESSION 
Levels of mRNA for HTR1A receptor increased on PT in comparison to TCPS, with further 
increases on SLA and mSLA surfaces (figure 34a). There was no difference between mRNA levels 
for HTR2A on TCPS and PT surfaces, however, levels decreased on SLA and mSLA in 
Figure 35: Surface characteristics modulate serotonin receptor gene expression. Human MSC gene 
expression of serotonin receptors a) HTR1A, b) HTR2A, c) HTR1B and d) HTR2B on TCPS, PT or SLA surfaces. 




comparison to TCPS and PT (figure 34b). There was no significant difference in expression of 
HTR2A on SLA in comparison with mSLA surfaces. mRNA levels for the HTR2B receptor were 
lower on PT in comparison to TCPS, with further decreases on SLA and the most significant 
decreases evident on mSLA surfaces (figure 34c). HTR2B mRNA levels also decreased on Ti 
substrates in comparison to TCPS (figure 34d). Levels were lower on PT and SLA in comparison 
to TCPS, with further decreases on mSLA surfaces. 
3.3.2. AIM 3.2: EXAMINE THE EFFECTS OF ANTIDEPRESSANT TREATMENT 
AND TI SURFACE CHARACTERISTICS ON HUMAN MSC SEROTONIN 
RECEPTOR GENE EXPRESSION 
To further investigate receptor expression in the presence of antidepressants on 
microstructured Ti surfaces, human MSCs were treated with antidepressants or serotonin while 
cultured on smooth (PT), rough (SLA) or rough and hydrophilic (mSLA) Ti surfaces throughout 
differentiation and mRNA levels for HTR1A, HTR1B, HTR2A and HTR2B were assessed. 
Serotonin Treatment Modulates Serotonin Receptor Expression 
Prior to any treatment with serotonin, expression of HTR1A was higher on PT, with further 
increases on SLA surfaces, when compared with TCPS (figure 35a). Conversely, expression for 
HTR1B, HTR2A and HTR2B decreased on SLA surfaces in comparison to TCPS and PT (figure 
35b, c and d). All concentrations of serotonin increased HTR1A receptor expression on TCPS and 
PT surfaces, in comparison to the no treatment control (figure 35a). On SLA surfaces, however, 
this effect was reversed as serotonin treatment dose-dependently decreased mRNA levels, with the 
10μM concentration having the most significant decreases, in comparison to the no treatment 
control.  
Treatment with serotonin at the lower concentrations increased mRNA levels for HTR2A 
and HTR1B on TCPS and PT surfaces, however, increasing the treatment concentration to 10μM 
significantly decreased levels in comparison to the no treatment control (figure 35b and c). All 
concentrations of serotonin increased levels for HTR2A and HTR1B on SLA surfaces in 
comparison to the no treatment control. Expression was sensitive to the dose, as the 10μM 
concentration seemed to have slightly lower expression levels when compared to the 1μM dose on 




SSRI Treatment Modulates Serotonin Receptor Expression 
In order to determine the effects of SSRIs on human MSC serotonin receptor expression 
while cultured on microstructured Ti surfaces, cells were treated with various concentrations of 
the SSRIs fluoxetine, sertraline or paroxetine while cultured on smooth (PT) or rough (SLA) Ti 
surfaces throughout differentiation and mRNA levels for HTR1A, HTR1B, HTR2A and HTR2B 
were assessed. Prior to any SSRI treatment, expression of HTR1A was significantly higher on 
SLA surfaces when compared with TCPS or PT (figures 36a, 37a and 38a). On the contrary, 
expression for HTR1B, HTR2A and HTR2B was lowest on SLA surfaces in comparison to TCPS 
and PT (figures 36b-d, 37b-d and 38b-d). 
Figure 36: Effects of serotonin treatment on serotonin receptor gene expression. MSC gene expression of a) 
HTR1A, b) HTR2A, c) HTR1B and d) HTR2B was measured after treatment with 0.1μM, 1μM or 10μM of 
serotonin on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 




Fluoxetine treatment does-dependently increased HTR1A expression on TCPS and PT in 
comparison to the no treatment control, with the highest levels seen after treatment with the 10μM 
concentration (figure 36a). This effect was reversed on SLA surfaces, as treatment decreased 
expression levels in comparison to the no treatment control, with the lowest expression after 
treatment with the 10μM concentration. Contrary to HTR1A, mRNA levels for HTR2A, HTR1B 
and HTR2B decreased with fluoxetine treatment on TCPS and PT in comparison to the no 
treatment control (figure 36b, c, d). Effects were dose-dependent for HTR2A levels on TCPS and 
PT, with the 10μM dose having the lowest expression (figure 36b). There were no significant 
differences in HTR1B mRNA levels between the 0.1μM fluoxetine dose and the no treatment 
control on TCPS and PT, and also for HTR2A on PT surfaces. Only the 10μM concentration 
Figure 37: Fluoxetine (SSRI) modulates serotonin receptor gene expression. MSC gene expression of a) 
HTR1A, b) HTR2A, c) HTR1B and d) HTR2B was measured after treatment with 0.1μM, 1μM or 10μM of 
fluoxetine on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 




decreased levels for HTR2B on TCPS and PT in comparison to the no treatment control (figure 
35d). 
On SLA surfaces, however, fluoxetine increased mRNA levels for HTR2A, HTR1B and 
HTR2B (figure 36b, c and d). Effects were dose-dependent for HTR2A expression, with the 
highest levels evident after treatment with the 10μM concentration. There were no significant 
differences between HTR1B mRNA levels after treatment with 0.1μM of fluoxetine in comparison 
to the no treatment control on SLA surfaces (figure 36c). A slight increase in HTR2B expression 
after 0.1μM of fluoxetine in comparison to the no treatment control was evident on SLA (figure 
36d). Treatment with the 1μM and 10μM concentrations increased mRNA levels for HTR1B and 
HTR2B, with the highest expression evident after the 1μM dose in comparison to the no treatment 
control. 
Figure 38: Sertraline (SSRI) modulates serotonin receptor gene expression. MSC gene expression of a) 
HTR1A, b) HTR2A, c) HTR1B and d) HTR2B was measured after treatment with 0.1μM, 1μM or 10μM of 
sertraline on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 




Effects of sertraline and paroxetine were assessed as previously described for fluoxetine. 
Only the 1μM and 10μM concentrations were used for treatments, as no significant differences in 
serotonin receptor expression were evident for the 0.1μM concentration of fluoxetine. Sertraline 
and paroxetine treatments dose-dependently increased mRNA levels for the HTR1A and HTR2A 
receptors on TCPS and PT in comparison to the no treatment control, with the highest expression 
levels evident after treatment with the 10μM dose (figure 37a, b and 38a and b). Only the 1μM 
concentration of sertraline slightly decreased expression on TCPS when compared to the no 
treatment group (figure 37a). The opposite effect was seen on SLA surfaces. Levels of HTR1A 
mRNA dose-dependently decreased after sertraline and paroxetine treatment, with the lowest 
levels evident with the 10μM dose in comparison to PT, the 1μM concentration and the no 
treatment control (figure 37a and 38a). Treatment with sertraline at the 10μM concentration 
produced lower expression levels than paroxetine on SLA surfaces. Sertraline significantly 
decreased levels of mRNA for HTR1A compared to TCPS, PT, the 1μM and the no treatment 
control when cells were cultured on SLA. All paroxetine treatments increased levels of HTR2A 
on SLA surfaces in comparison to the no treatment control, with the highest expression evident 
after treatment with the 1μM concentration (figure 38b). Only the 1μM concentration of sertraline 
increased HTR2A mRNA levels in comparison to the no treatment control on SLA surfaces (figure 
37b). Treatment with 10μM significantly decreased expression in comparison to TCPS, PT, the 




All concentrations of sertraline dose-dependently decreased HTR1B mRNA levels on 
TCPS, PT and SLA surfaces in comparison to the no treatment control, with the lowest levels 
evident after treatments with the 10μM concentration (figure 36c). Expression levels were lower 
on PT surfaces after 10μM sertraline treatments in comparison to TCPS, with further decreases on 
SLA surfaces. Dose-dependent decreases for HTR1B levels were similar after paroxetine 
treatment, but only on TCPS and PT surfaces (figure 37c). On SLA surfaces, however, both 
concentrations of paroxetine increased HTR1B expression, with the 1μM having the highest levels 
in comparison to the no treatment control. Sertraline treatment dose-dependently stimulated 
HTR2B expression on TCPS and PT surfaces with the highest levels evident after treatment with 
the 10μM concentration, while paroxetine had the opposite effect (figure 36d and 37d). Only the 
1μM dose of sertraline increased HTR2B levels on SLA surfaces in comparison to the no treatment 
Figure 39: Paroxetine (SSRI) modulates serotonin receptor gene expression. MSC gene expression of a) 
HTR1A, b) HTR2A, c) HTR1B and d) HTR2B was measured after treatment with 0.1μM, 1μM or 10μM of 
paroxetine on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 




control. Treatment with 10μM of sertraline had the most significant decreases in HTR2B 
expression when compared with TCPS, PT, the 1μM concentration and the no treatment group. 
Both the 1μM and 10μM paroxetine doses increased HTR2B mRNA levels on SLA surfaces in 
comparison to the no treatment control, with the 1μM dose having the highest expression levels. 
SNRI Treatment Modulates Serotonin Receptor Expression 
In order to assess the effects of antidepressants within the SNRI class on gene expression 
of serotonin receptors by human MSCs, cells were treated with 1μM or 10μM concentrations of 
duloxetine, a commonly prescribed SNRI. Dose-dependent increases of HTR1A expression was 
evident on TCPS and PT with an increase in duloxetine dose as compared to the no treatment 
control (figure 39a). This effect was reversed, however, on SLA surfaces. Duloxetine treatment 
decreased HTR1A expression with the increase in drug concentration when compared to the no 
treatment control. Treatment with 1μM of duloxetine increased mRNA levels of HTR2A on all 
surfaces in comparison to the no treatment control (figure 39b). Increasing the dose to 10μM had 
the lowest levels in comparison to the 1μM concentration and the no treatment control on TCPS 
and PT surfaces. Treatment with the 10μM concentration decreased HTR2A mRNA levels when 
compared to the 1μM treatments on SLA surfaces, but levels were still slightly higher than the no 
treatment controls. 
Duloxetine treatment does-dependently decreased HTR1B expression levels on TCPS and 
PT in comparison to the no treatment control, however, expression increased on SLA surfaces by 
treatments, with the 1μM concentration having the highest levels in comparison to the 10μM and 
the no treatment control (figure 39c). Only the 10μM concentration significantly decreased 
HTR2B expression on TCPS in comparison to the no treatment control (figure 39d). Treatment 
with the 1μM dose of duloxetine increased expression in comparison to the no treatment control, 




concentrations increased expression levels on SLA surfaces, with the highest levels evident after 
treatment with the 1μM concentration of duloxetine, when compared to the no treatment control. 
Other Antidepressant Treatment Modulates Serotonin Receptor Expression 
 Trazodone and bupropion are also two very commonly prescribed antidepressants, but they 
do not belong to a specific class. Their effects on serotonin receptor expression by MSC was 
assessed in a similar way. Cells were cultured on PT or SLA surfaces and compared to those on 
TCPS while being treated with either 1μM or 10μM concentrations of trazodone or bupropion. 
Serotonin receptor expression was evaluated after treatments. Only the 10μM concentration of 
trazodone increased HTR1A receptor expression on TCPS when compared to the no treatment 
control (figure 40a). Treatment at the 1μM concentration had the highest expression levels, and 
Figure 40: Duloxetine (SNRI) modulates serotonin receptor gene expression. MSC gene expression of a) 
HTR1A, b) HTR2A, c) HTR1B and d) HTR2B was measured after treatment with 0.1μM, 1μM or 10μM of 
duloxetine on TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 




10μM treatments had the lowest, when compared to the no treatment control on PT surfaces. All 
treatments dose-dependently decreased HTR1A expression levels on SLA surfaces, with the 10μM 
concentration having the lowest levels, in comparison to the no treatment control. Expression 
levels for HTR2A were highest after treatment with 1μM of trazodone on TCPS, PT and SLA 
surfaces when compared to the 1μM concentration and the no treatment control (figure 40b). The 
10μM treatments decreased expression on TCPS but there was no difference between the 10μM 
concentration and the no treatment control on PT surfaces. Both trazodone concentrations 
increased HTR2A expression levels on SLA surfaces in comparison to the no treatment control, 
with the 1μM concentration having the highest levels. Treatments with trazodone at either 
concentration was inhibitory for HTR1B expression levels on TCPS and PT surfaces, with the 
highest concentration having the lowest levels of mRNA in comparison to the no treatment control 
a) b) 
c) d) 
Figure 41: Trazodone modulates serotonin receptor gene expression. MSCs gene expression for a) HTR1A, 
b) HTR2A, c) HTR1B and d) HTR2B after treatment with 0.1μM, 1μM or 10μM of trazodone on TCPS, PT or 




(figure 40c). The reverse was true on SLA surfaces, as both concentrations increased expression, 
with the highest levels evident after treatment with the 1μM dose, when compared to the no 
treatment control. Expression of HTR2B dose-dependently increased after trazodone treatment on 
all surfaces in comparison to the no treatment control, with the highest levels evident after 
treatment with the 10μM concentration (figure 40d). 
Bupropion treatments dose-dependently increased HTR1A expression levels on TCPS and 
PT in comparison to the no treatment control, with the highest levels evident after treatment with 
the 10μM concentration (figure 41a). On SLA surfaces, treatments decreased expression in 
comparison to the no treatment control, with the lowest seen after treatment with 1μM doses. 
Expression of HTR2A dose-dependently decreased on TCPS, and increased on SLA surfaces, 
when compared to the no treatment control (figure 41b). Only the 1μM concentration decreased 
expression on PT surfaces, in comparison to the no treatment control. The 10μM dose increased 
a) b) 
c) d) 
Figure 42: Bupropion modulates serotonin receptor gene expression. MSCs gene expression for a) HTR1A, 
b) HTR2A, c) HTR1B and d) HTR2B after treatment with 0.1μM, 1μM or 10μM of bupropion on TCPS, PT or 




expression when compared to the 1μM, but there were no significant differences between the 
10μM dose and the control. Expression of HTR1B also followed dose-dependent decreases on 
TCPS and PT surfaces in comparison to the no treatment control, with the lowest levels evident 
after treatment with the highest concentration (figure 41c). Expression increased after treatment 
with 1μM concentration of bupropion, however, increasing the dose to 10μM significantly 
decreased expression when compared to the 1μM concentration and the no treatment control on 
SLA surfaces. There was no difference in HTR2B expression between the 1μM concentration and 
the no treatment control on TCPS or PT surfaces, however, augmenting the dose to 10μM 
significantly decreased expression (figure 41d). Treatment with 1μM of bupropion increased 
expression on SLA surfaces in comparison to the no treatment control. The 10μM concentration 
lowered expression in comparison to the 1μM dose, but was not statistically significant when 
compared to the no treatment control. 
3.3.3. AIM 3.3: INVESTIGATE THE EFFECTS OF SEROTONIN RECEPTOR 
INHIBITION ON HUMAN MSC PRODUCTION OF BONE REMODELING 
SIGNALING ON TI SURFACES 
Studies in aim 3.3 were performed to investigate whether serotonin receptors play a role in 
human MSC local factor secretion of proteins involved in bone remodeling processes, and how 
these effects are modulated by Ti surface roughness. Human MSCs were treated with different 
types of serotonin receptor inhibitors specific for HTR1A, HTR1B, HTR2A and the HTR2B receptors 
while being cultured on PT or SLA surfaces and compared to those on TCPS. Cells were treated 
throughout differentiation for 7 days, then levels of secreted OPG and RANKL were measured. 
The hypothesis is that if a serotonin receptor is involved in bone remodeling processes, then it will 
alter OPG or RANKL protein production by the MSCs according to surface roughness. 
Serotonin Receptor Inhibition 
In order to examine whether the HTR1A receptor is involved in modulating OPG and 
RANKL levels, human MSCs were treated with 1µM of WAY-100635, an HTR1A receptor 
inhibitor. Prior to any inhibition, secreted levels of OPG and RANKL were higher on Ti surfaces 
in comparison to TCPS (figures 42, 43, 44, 45 and 46). Treatment with the HTR1A inhibitor 




treatment control, with further decreases on SLA surfaces in comparison to the control, PT and 
SLA (figure 42).  
Human MSC HTR2A inhibition was achieved by treatment with 1µM of RH-34, an HTR2A 
inhibitor, for 7 days throughout differentiation on PT, SLA or TCPS surfaces. There were no 
significant differences in secreted OPG levels on TCPS, PT or SLA surfaces after HTR2A 
inhibition when compared to the no treatment control (figure 43a). However, RANKL levels 
decreased in comparison to the no treatment control post HTR2A inhibition all surfaces (figure 
43b).  
MSCs were treated in the same manner as above but with either SB-224289 or RS-127445, 
HTR1B or HTR2B inhibitors. Blocking the HTR1B and HTR2B receptors had no effect on secreted 
Figure 43: Effects of HTR
1A
 on bone remodeling. Human MSC secreted protein levels were measured for a) 
OPG and b) RANKL after inhibition of HTR
1A
 receptor with 1µM treatment of WAY-100635 while cultured on 
TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 a vs. 0µM. 
a) b) 
Figure 44: Effects of HTR
2A
 on bone remodeling. Human MSC secreted protein levels were measured for a) 
OPG and b) RANKL after inhibition of HTR
2A
 receptor with 1µM treatment of RH-34 while cultured on TCPS, 





OPG or RANKL protein levels on any of the surfaces (figures 43 and 44). Treatment with all of 
the inhibitors combined showed similar effects as those of the HTR1A inhibition (figure 45). There 
were no significant differences in OPG protein levels after inhibition of all four of the serotonin 
receptors on TCPS in comparison to the no treatment control (figure 45a). However, on Ti surfaces, 
receptor inhibition decreased protein levels on PT in comparison to the no treatment control, with 
further decreases on SLA surfaces when compared to TCPS, PT and the no treatment control. 




Figure 46: Effects of HTR
2B
 on bone remodeling. Human MSC secreted protein levels were measured for a) 
OPG and b) RANKL after inhibition of HTR
2B
 receptor with 1µM treatment of RS-127445 while cultured on 
TCPS, PT or SLA surfaces. Between surfaces: P < 0.05 # vs. TCPS, $ vs. PT. Per surface: P < 0.05 a vs. 0µM. 
a) b) 
Figure 45: Effects of HTR
1B
 on bone remodeling. Human MSC secreted protein levels were measured for a) 
OPG and b) RANKL after inhibition of HTR
1B
 receptor with 1µM treatment of SB-224289 while cultured on 
















Figure 47: Effects of serotonin receptors inhibition on bone remodeling. MSC secreted proteins were measured 
for a) OPG and b) RANKL after inhibition of HTR1A, HTR1B, HTR2A and HTR2B serotonin receptors with 
1µM treatment of all the inhibitors combined while cultured on TCPS, PT or SLA surfaces. Between surfaces: P 





CHAPTER 4 DISCUSSION 
 
 
The findings presented in this work demonstrate the detrimental effects of frequently 
prescribed antidepressants on bone formation and remodeling on clinically relevant Ti surfaces 
commonly used in dental applications. Antidepressants inhibited human MSC differentiation and 
decreased protein levels associated with bone formation while increasing those involved in bone 
resorption on microstructured Ti surfaces. The drugs also increased osteoclastic activity both 
directly and through treated MSCs, with the highest levels evident after treatment with conditioned 
media from MSCs on microstructured Ti surfaces. Our findings suggest that osteoclastic activity 
is mediated through increased RANKL production, which is regulated by serotonin receptor 
HTR2A. 
Clinically, the use of microstructured implants have higher success rates than smooth ones 
in that they have been shown to reduce healing time, improve mechanical stability and provide 
greater bone-implant contact [29]. In vitro studies have also demonstrated that microstructured Ti 
substrates increased human MSC differentiation without the addition of osteogenic supplements 
[31]. Topographical modifications at the implant surface created a roughened surface topography, 
which was adequate enough on its own to induce differentiation in human MSCs. However, despite 
the high success rate of rough implants in healthy recipients, patients taking antidepressant 
medications, especially those in the SSRI category, have an increased risk of dental implant failure, 
decreased bone mineral density and an increased risk of fractures [3]. 
Antidepressants achieve therapeutic effects by increasing extracellular concentrations of 
synaptic serotonin. This is facilitated by blocking the functionality of the serotonin transporter in 
the brain, as well as on various cells throughout the body. Higher levels of systemic serotonin may 
have detrimental effects on the quality of bone. Serotonergic functions have previously been 
thought to be restricted to the brain, however, serotonin has recently been shown to be important 
in bone metabolism. Peripherally-derived serotonin accounts for the majority of serotonin 
production in the body. Additionally, the neurotransmitter is unable to readily cross the blood-




peripheral ones. Since a lesser amount of serotonin positively favors bone mass accrual in the brain 
in comparison to the majority that is produced peripherally, effects of peripheral serotonin are the 
most concerning in terms of bone metabolism. 
Effects of serotonin may be modulated by various types and doses of antidepressants. 
Although there has been an increase in research efforts regarding the effects of SSRIs on bone, the 
capacity of bone formation during antidepressant exposure surrounding biomaterials has yet to be 
elucidated. Work done in this thesis demonstrates the in vitro capacity of bone formation on Ti 
substrates commonly utilized for dental implant applications under exposure of the most frequently 
prescribed categories of antidepressants. Bone formation was assessed by early and late 
osteoblastic differentiation markers and secreted local factors produced by MSCs on Ti surfaces. 
Ti surface roughness effects on these processes were also assessed during various concentrations 
of serotonin or antidepressant treatments. These studies provide valuable insight into the in vivo 
processes involved with antidepressant use with biomaterial applications. 
Prescribed doses of SSRIs in humans vary between each drug. Fluoxetine, the most 
commonly prescribed SSRI in the U.S., is given in doses of 10, 20 or 40mg capsules in order to 
achieve a therapeutic range of around 0.5-2.5µM in the blood [11]. The 1µM concentration used 
in these studies was chosen as a low dose to simulate such therapeutic ranges while investigating 
the effects of the drugs on MSC differentiation. However, increasing evidence of SSRI 
bioaccumulation have been documented at much greater concentrations in the bone marrow in 
comparison to those in the blood [36]. Reports of fluoxetine levels being as high as 100μM in 
human bone marrow of patients taking the drug, and traces were still detected 3 months after the 
treatment was discontinued [42]. The 10µM concentration used in these studies was used to 
investigate the effects of the drugs at a higher dose. Such concentrations detected in the bone 
marrow are much greater than the highest concentration used in these studies, suggesting larger 
potential toxicity and greater decreases in MSC differentiation capacity with increased prescription 
doses and longer duration of treatments. 
Quantification of human MSC DNA concentrations on Ti substrates prior to any serotonin 
or antidepressant treatment showed the cells interacting with and attaching to the substrates which 




microstructured surfaces than on TCPS or smooth Ti. Early and late osteoblastic differentiation 
marker expression of RUNX2 and BGLAP, respectively, was also higher on rough surfaces than 
smooth or TCPS. Similar results were established in prior studies [8], and collectively, these 
responses are indicative of MSC differentiation towards an osteoblastic lineage. Similar levels of 
DNA were evident after treatment with serotonin at all concentrations on each surface when 
compared to the no treatment controls, suggesting that serotonin treatment is not detrimental to 
cell survival. However, when the cells were treated with higher concentrations of antidepressants 
(10µM), DNA content was significantly decreased on all surfaces. Although we did not perform 
cytotoxic assays in these studies, decreased DNA levels after treatments with higher concentrations 
of antidepressants suggests that the cells are sensitive to the dose and were unable to survive with 
the increase in treatment concentration. 
Serotonin has been shown to be an important regulator in bone metabolism. This was 
evident in these studies, as physiologically relevant concentrations of serotonin enhanced 
expression of RUNX2 and BGLAP osteoblastic differentiation markers when MSCs were plated 
on plastic or smooth Ti surfaces. Effects were dose-sensitive, as lower doses (1µM) seemed to 
induce greater expression of osteoblastic differentiation markers compared to higher ones (10µM). 
However, when cells were cultured on rough Ti surfaces in this work, all concentrations of 
serotonin affected MSC differentiation by decreasing expression of early and late osteoblastic 
markers. This was further confirmed by decreases in alkaline phosphatase specific activity (early 
marker of osteoblastic differentiation) as well as secreted OCN (late marker) protein levels in the 
media. These effects of serotonin treatment were only evident on rough Ti surfaces, and were not 
apparent on plastic or smooth Ti surfaces. Antidepressants, and higher concentrations of serotonin, 
impaired the osteoblastic differentiation potential of human MSCs and decreased protein levels 
important for the osteogenic and angiogenic environment. ALP and OCN are proteins produced 
and secreted by osteogenic cells and are essential for bone formation, and therefore, a decrease in 
their expression by elevated serotonin levels illustrates a decreased ability of MSCs to differentiate 
and form bone. These responses were exacerbated on rough Ti surfaces, as cells seemed to be 




Cells cultured on rough Ti surfaces were more susceptible to serotonin and antidepressant 
treatment than those on TCPS or smooth PT. These effects can be explained by the materials’ 
surface characteristics. It has been shown that MSCs grown on microstructured Ti are more 
differentiated than those on smooth surfaces, as measured by increases in osteoblastic 
differentiation markers [31]. It is possible that cells undergoing differentiation, as induced by 
surface characteristics, are more affected by the drugs than those not in a differentiation state (on 
TCPS). Cells on rough surfaces may utilize certain signaling mechanisms which are critical to 
their differentiation process, and such signaling may be altered by serotonin or antidepressants, 
where as non-differentiated cells (cells cultured on TCPS) are not susceptible in the same manner. 
Higher doses of serotonin or antidepressants exhibited greater inhibition of MSC 
differentiation and lower protein levels on rough surfaces compared with smooth or plastic, as 
measured by decreases in alkaline phosphatase specific activity and secreted OCN, OPG, BMP-2 
and VEGF protein levels. However, not all antidepressants performed equally. Those within the 
SSRI family showed significantly lower levels of proteins associated with bone formation when 
compared to other types of antidepressants which are not as selective for serotonin, such as 
duloxetine (SNRI), trazodone or bupropion. Sertraline seemed to be the antidepressant that 
affected bone formation the most, as measured by having the most significant decreases in OCN 
and VEGF protein levels. Furthermore, secreted OPG protein levels by MSCs treated with the high 
dose of sertraline and cultured on rough Ti surfaces were so low they could not be detected. It is 
possible that the drug is affecting other vital protein production or secretion at this particular dose. 
Similar results were published by Fraher et al., where human adipose tissue-derived MSCs showed 
significant osteoblastic differentiation inhibition on plastic substrates by measuring decreases in 
ALP activity as well as RUNX2 mRNA levels after treatment with the same high dose (10µM) 
concentration of sertraline used in this work [4]. 
These findings are of important relevance, as most in vitro studies explore cellular 
processes using TCPS, however, it has been shown that cells are sensitive to surface characteristics 
such as roughness, chemistry and energy, and more importantly, modulate their functions 
accordingly. Thus, results obtained from TCPS surfaces are not the best representation of the 




the materials of choice for applications in healing and regeneration, and so, cellular effects during 
antidepressant exposure are more accurately represented on clinically relevant biomaterial 
surfaces. 
It is necessary for osteogenic cells to control their microenvironment in order to 
successfully support the formation of new bone. Osteoblastic cells produce proteins in their local 
environment as a form of communication with other cells to promote osteogenesis, angiogenesis 
and regulate bone remodeling processes. Cells surrounding an implant can regulate themselves 
and those located distally via autocrine and paracrine means by secretions of BMP-2, and VEGF. 
Osteoblastic lineage cells also secrete OPG and RANKL for communication with osteoclastic cells 
and regulating bone remodeling process. Imbalances in secreted protein levels may affect 
osteogenic capability, bone quality and delay implant osseointegration. While the greatest 
production of BMP-2, OPG, RANKL and VEFG was evident on rough Ti surfaces, MSCs treated 
with antidepressants or serotonin had significant decreases in these protein levels. Higher doses of 
serotonin or antidepressants exhibited even lower protein levels on rough surfaces compared with 
smooth or plastic, as measured by decreases in secreted OPG, BMP-2 and VEGF protein levels. 
Conversely, RANKL production significantly increased on rough Ti surfaces after treatment with 
antidepressants.  
Interestingly, not all antidepressants performed equally. Those within the SSRI family 
showed significantly lower levels of proteins important for bone formation when compared to 
other types of antidepressants which are not as selective for serotonin. Of all SSRIs used in these 
studies, sertraline seemed to be the drug that affects the highest bone formation, as measured by 
having the most significant decreases in OCN and VEGF and increases in RANKL protein levels. 
Furthermore, secreted OPG protein levels by MSCs treated with the high dose of sertraline and 
cultured on rough Ti surfaces were so low they could not be detected. 
Serotonin and antidepressants had direct effects on osteoclastic activity by increasing levels 
of enzymatic TRAP activity when treated with higher concentrations of serotonin or fluoxetine. 
These results parallel the work done by Gustafsson et al. demonstrating expression of serotonin 
receptors and the transporter by osteoclasts [11] and Chabbi-Achengli et al., showing the 




of osteoclasts with conditioned media from MSCs treated with antidepressants had higher TRAP 
activity when compared to the control. Osteoclasts were affected by factors present in the 
conditioned media as a result of MSC treatment with antidepressants, as measured by increases in 
TRAP activity, and is an indication that bone resorption may be increased. On the contrary, other 
types of antidepressants such as duloxetine, an SNRI, decreased TRAP activity at the high dose of 
treatment. Furthermore, when factors produced by MSCs in the conditioned media as a result of 
antidepressant treatment were used to treat osteoclasts, osteoclastic activity was also affected, as 
measured by significant increases in TRAP activity according to dose and the Ti substrate from 
which the conditioned media was collected from. The highest levels of TRAP activity were evident 
in cells treated with conditioned media where MSCs were grown on rough Ti surfaces.  
Direct treatment of osteoclast precursors did not reflect the same effects on TRAP activity 
as indirect treatment by conditioned media. TRAP activity decreased when cells were directly 
treated with the high dose of duloxetine. However, when osteoclasts were exposed to conditioned 
media from duloxetine-treated MSCs at the same concentration, TRAP activity increased. An 
explanation for this may be that other factors, such as interleukins produced by the cells as a 
response to antidepressant treatment, could be contributing to TRAP activity, in addition to the 
increased RANKL production. Higher concentrations of extracellular serotonin can enhance 
production and secretion of interleukin 1 beta (IL-1β) and interferon gamma (IFN-γ) pro-
inflammatory cytokines by cells possessing serotonin receptors [46].  
Work done in these studies suggests that dental implant failure in individuals taking 
antidepressants could be caused in part by antidepressant-induced imbalances in the OPG/RANKL 
system. Misregulation in this signaling could have an effect on bone quality surrounding a Ti dental 
implant, which can have direct effects on its osseointegration and ultimate success. Prior to any 
drug treatment, OPG and RANKL protein production by osteogenic cells increased on 
microstructured Ti surfaces, and similar results were shown in prior studies [47]. Antidepressant 
treatment decreased OPG and further increased RANKL levels. The presence of excessive 
amounts of RANKL by antidepressant use may overwhelm the already decreased levels of OPG, 
increasing the chance for RANK to bind to RANKL and supporting osteoclastic bone resorption. 




implant. In this scenario, osteoblasts may continue to differentiate and deposit new bone matrix, 
however, the rate of differentiation will be severely affected by the drug, and matrix deposition 
may be much slower in comparison to the rate of resorption by the osteoclasts. Higher osteoclastic 
activity may leave many unfilled resorption pits, and overtime, bone quality will worsen. Since 
osseointegration of dental implants is dependent on the quality of bone, chronic antidepressant use 
may delay the osseointegration process, ultimately leading to implant failure. 
Antidepressants elevate systemic concentrations of serotonin, which encompasses the 
majority of levels in the body. Serotonin then modulates its effects on bone through its various 
receptors. Work performed in these studies not only demonstrates MSC expression of serotonin 
receptors, but more importantly, cells modulated this expression according to surface 
characteristics. All receptor expression decreased with increasing surface roughness, with the 
exception of HTR1A, and treatment with serotonin or antidepressants further modulated these 
effects. It is suggested that HTR1A may be involved in differentiation and this is inhibited by 
antidepressant use.  
Prior studies indicate that the HTR2A receptor is highly expressed in comparison to all other 
receptors and their isoforms [9] and [10]. With respect to these findings, serotonin may be 
modulating bone metabolism and exhibiting its actions mostly through this receptor. In these 
studies, human MSCs does-dependently increased expression of this receptor on rough surfaces in 
comparison to smooth or TCPS. In addition, when treated with fluoxetine, HTR2A expression by 
MSCs increased incrementally with the increasing dose on rough Ti surfaces. Such results may be 
an indication that fluoxetine enhances expression of this receptor in bone with increasing doses. 
This may be remarkably detrimental on bone quality, given that a higher dose may further magnify 
these effects. 
The potential role of each serotonin receptor was individually assessed in bone remodeling 
processes. Blocking HTR1B and HTR2B on MSCs with their specific inhibitors did not affect OPG 
or RANKL production, however, blocking HTR1A significantly decreased OPG and RANKL 
protein levels in comparison to the control, but within similar amounts. HTR2A inhibition only 




in modulating the OPG/RANKL ratio and production by MSCs and their functions regulate signals 
produced to communicate and activate osteoclast activity. 
Some limitations of this work are that all studies were completed in vitro. Although these 
studies demonstrate the negative effects of SSRIs on MSC differentiation and bone formation, in 
vivo investigations should also be performed in order to understand the full mechanisms of the role 
of serotonin and antidepressants in bone metabolism surrounding microstructured Ti implants. 
This thesis work describes in vitro effects of serotonin and antidepressants. However, such effects 
may not be the same when studied in vivo, as there are many confounding factors involved. For 
instance, inactivation of 5-HTT via an SSRI will enhance central and peripheral serotonin 
concentrations. However, negative feedback mechanisms may be activated in response to this 
peripheral serotonergic signaling, as well as other cells may be involved in these processes. 
Furthermore, studies performed for investigation of the effects of antidepressants on bone 
remodeling signals between MSCs and osteoclasts utilize conditioned media obtained from MSCs 
from only the last 24 hours of the experiment. This design fails to take into account the real-time 
interactions between each cell type throughout differentiation and in response to the drugs. In this 
case, factors produced by MSCs on microstructured Ti surfaces could play a role in mitigating 
osteoclastic TRAP activity. Osteoclasts may also produce factors in response to this signaling to 
further contribute to TRAP activity. Additionally, studies performed in this work utilize fixed 
concentrations of different types of antidepressants. The same concentrations of different drugs 
were used for treatment as a uniform way to accurately compare various drugs within different 
categorizes. However, not all antidepressants are equal in that many of them differ in chemical 
composition and efficacy and will not have the same toxicities. 
 Work in this thesis provides insight into the deleterious effects of antidepressant 
medication use on bone formation and remodeling signaling during interactions with 
microstructured Ti biomaterials. Antidepressants within the SSRI class exhibited the most negative 
effects on bone formation and remodeling signaling in comparison to antidepressants that are both 
serotonin and norepinephrine inhibitors. These findings are of great interest when taking into 
account the frequency of SSRI prescriptions and the increasing demands for microstructured Ti 




osteoporosis are at an even greater risk for implant failure. Clinicians should be aware of the type 
of antidepressant, the dose and the length of time a patient is under treatment and caution should 
be taken when considering a dental implant. Additionally, future directions for this work should 
target therapeutic compounds that specifically block HTR2A signaling on MSCs to alleviate 
negative effects on bone. Other compounds may be considered as a synergistic treatment with 
antidepressants in order to salvage some of the deleterious effects on bone. This approach may be 







CHAPTER 5 CONCLUSION 
 
 
This thesis evaluated the in vitro effects of antidepressants on bone formation during 
interactions with clinically relevant microstructured Ti surfaces. This work indicates that 
antidepressants inhibit human MSC differentiation, decrease local factor production of proteins 
associated with bone formation and increases those involved in bone resorption. These effects were 
intensified by Ti surface characteristics, specifically rough, microstructured surfaces. It is 
suggested that these effects may be mediated through the presence of various serotonin receptors 
located on cell membranes of human osteogenic cells. Furthermore, cells are sensitive to Ti surface 
topography and modify serotonin receptor expression according to the surface roughness and 
antidepressant treatment further modulated these effects. Results in this work also suggest a role 
of antidepressants in regulation of bone remodeling, predominantly on microstructured Ti surfaces. 
These processes are vital for the quality of bone and are tightly associated with successful 
osseointegration of dental implants. As a result, work done in this thesis provides further insight 
in the understanding of bone formation and remodeling signaling surrounding microstructured Ti 
biomaterials in response to chronic prescription use and its overall effect on the ultimate success 
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